No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d2f3fA_, 1.0000, 0.00, 1.000, 375, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
2, d3qbhA_, 0.9984, 0.27, 1.000, 375, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
3, d2f3fB_, 0.9982, 0.31, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
4, d2f3eA_, 0.9980, 0.34, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
5, d4d8cA_, 0.9975, 0.36, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
6, d4d83A_, 0.9975, 0.37, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
7, d3pi5A_, 0.9975, 0.38, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
8, d3k5dA_, 0.9974, 0.36, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
9, d2f3eB_, 0.9973, 0.39, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
10, d3k5dC_, 0.9972, 0.38, 1.000, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
11, d1ym2A_, 0.9968, 0.42, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
12, d4lxkA_, 0.9967, 0.45, 0.997, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
13, d4lxmA_, 0.9965, 0.44, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
14, d3pi5B_, 0.9965, 0.44, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
15, d4d83B_, 0.9963, 0.45, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
16, d4lxaA_, 0.9962, 0.48, 0.997, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
17, d4lxkB_, 0.9961, 0.46, 1.000, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
18, d3k5gA_, 0.9961, 0.46, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH BJC060
19, d3k5cA_, 0.9961, 0.46, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH NB-216
20, d4lxaB_, 0.9960, 0.46, 1.000, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
21, d4d8cB_, 0.9960, 0.47, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
22, d3k5cB_, 0.9957, 0.49, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH NB-216
23, d3qbhB_, 0.9956, 0.51, 0.997, 376, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
24, d3k5gB_, 0.9956, 0.49, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH BJC060
25, d3k5fB_, 0.9956, 0.50, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH AYH011
26, d3dv5A_, 0.9955, 0.50, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
27, d3dv1A_, 0.9954, 0.51, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
28, d4lxmB_, 0.9952, 0.52, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
29, d2f3fC_, 0.9951, 0.55, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
30, d3cidB_, 0.9942, 0.58, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH726222
31, d3cicB_, 0.9942, 0.58, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH709583
32, d3qbhC_, 0.9941, 0.59, 1.000, 375, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
33, d3cibB_, 0.9940, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH727596
34, d1xn2A_, 0.9940, 0.58, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
35, d3dv1B_, 0.9939, 0.59, 1.000, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
36, d2qp8B_, 0.9939, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH734723
37, d2qmgB_, 0.9939, 0.60, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH745966
38, d2qmfB_, 0.9939, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH735310
39, d1fknB_, 0.9939, 0.58, 1.000, 389, 375, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
40, d3l58B_, 0.9937, 0.61, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH589432
41, d2qmdB_, 0.9937, 0.60, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH722924
42, d2qk5B_, 0.9937, 0.60, 1.000, 389, 375, STRUCTURE OF BACE1 BOUND TO SCH626485
43, d1m4hB_, 0.9937, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
44, d1xn3C_, 0.9936, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
45, d2qmfA_, 0.9935, 0.60, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH735310
46, d2g94B_, 0.9935, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
47, d2g94A_, 0.9935, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
48, d2f3eC_, 0.9935, 0.63, 1.000, 381, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
49, d3l58A_, 0.9934, 0.61, 1.000, 395, 375, STRUCTURE OF BACE BOUND TO SCH589432
50, d3k5dB_, 0.9934, 0.62, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
51, d3cibA_, 0.9934, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH727596
52, d2qmgA_, 0.9934, 0.60, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH745966
53, d2g94D_, 0.9934, 0.61, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
54, d1xn3D_, 0.9934, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
55, d1xn2B_, 0.9934, 0.61, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
56, d3cicA_, 0.9933, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH709583
57, d2zhrA_, 0.9933, 0.61, 1.000, 390, 375, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
58, d2qmdA_, 0.9933, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH722924
59, d1ym2B_, 0.9933, 0.65, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
60, d2g94C_, 0.9932, 0.61, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
61, d1m4hA_, 0.9932, 0.62, 1.000, 391, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
62, d3cidA_, 0.9931, 0.62, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH726222
63, d2qk5A2, 0.9931, 0.62, 1.000, 393, 375, STRUCTURE OF BACE1 BOUND TO SCH626485
64, d1xn2D_, 0.9931, 0.62, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
65, d1xn2C_, 0.9931, 0.62, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
66, d2qp8A_, 0.9930, 0.62, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH734723
67, d1ym2C_, 0.9930, 0.64, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
68, d2vkmC_, 0.9929, 0.63, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
69, d1fknA_, 0.9929, 0.64, 1.000, 391, 375, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
70, d3pi5C_, 0.9928, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
71, d3dv5B_, 0.9928, 0.66, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
72, d4lxkC_, 0.9927, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
73, d4d8cC_, 0.9927, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
74, d4d83C_, 0.9927, 0.66, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
75, d3dv5C_, 0.9926, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
76, d3kn0B_, 0.9921, 0.68, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH708236
77, d4lxaC_, 0.9920, 0.69, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
78, d3kmxB_, 0.9920, 0.68, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH346572
79, d2vkmD_, 0.9920, 0.67, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
80, d3l5fB_, 0.9919, 0.68, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH736201
81, d3qi1A_, 0.9917, 0.68, 0.995, 382, 375, DESIGN AND SYNTHESIS OF HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS: PRIME SIDE CHROMANE-CONTAINING INHIBITORS
82, d4h3fB_, 0.9916, 0.70, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
83, d3k5gC_, 0.9916, 0.70, 1.000, 381, 375, HUMAN BACE-1 COMPLEX WITH BJC060
84, d1xs7D_, 0.9915, 0.70, 1.000, 389, 375, CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
85, d4djxB_, 0.9914, 0.71, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
86, d3dv1C_, 0.9914, 0.71, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
87, d2p4jC_, 0.9913, 0.73, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
88, d4h3jB_, 0.9912, 0.72, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
89, d4fslB_, 0.9912, 0.57, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
90, d3kmyB_, 0.9912, 0.72, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH12472
91, d3k5fC_, 0.9912, 0.72, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH AYH011
92, d4lxmC_, 0.9911, 0.73, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
93, d4fslE_, 0.9911, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
94, d4fslD_, 0.9911, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
95, d4fslA_, 0.9911, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
96, d3kmxA_, 0.9911, 0.71, 1.000, 395, 375, STRUCTURE OF BACE BOUND TO SCH346572
97, d2p4jA_, 0.9911, 0.73, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
98, d4djyB_, 0.9910, 0.73, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
99, d2p4jB_, 0.9909, 0.73, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
100, d2vkmA_, 0.9907, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
101, d4h3iB_, 0.9906, 0.73, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
102, d3kmyA_, 0.9906, 0.73, 1.000, 395, 375, STRUCTURE OF BACE BOUND TO SCH12472
103, d1xn3B_, 0.9906, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
104, d4h3gB_, 0.9905, 0.74, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
105, d4fs4A_, 0.9905, 0.73, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
106, d3l5fA_, 0.9905, 0.72, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH736201
107, d1xn3A_, 0.9905, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
108, d4gidC_, 0.9903, 0.75, 1.000, 388, 375, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
109, d3k5cC_, 0.9903, 0.76, 1.000, 381, 375, HUMAN BACE-1 COMPLEX WITH NB-216
110, d2vkmB_, 0.9903, 0.77, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
111, d1sgzC_, 0.9903, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
112, d1sgzB_, 0.9903, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
113, d1sgzA_, 0.9903, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
114, d4djxA_, 0.9902, 0.74, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
115, d4djuB_, 0.9902, 0.77, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
116, d4h3fA_, 0.9901, 0.74, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
117, d1sgzD_, 0.9901, 0.76, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
118, d3l5eA_, 0.9899, 0.75, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH736062
119, d3l59B_, 0.9899, 0.80, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH710413
120, d4djuA_, 0.9898, 0.76, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
121, d3l5dB_, 0.9898, 0.81, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH723873
122, d3l59A_, 0.9898, 0.76, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH710413
123, d4djwA_, 0.9896, 0.77, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
124, d4djyA_, 0.9895, 0.76, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
125, d2p4jD_, 0.9895, 0.80, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
126, d4h3jA_, 0.9893, 0.79, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
127, d4djvA_, 0.9893, 0.80, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
128, d4djwB_, 0.9890, 0.87, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
129, d4djvB_, 0.9890, 0.87, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
130, d4h3gA_, 0.9888, 0.78, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
131, d4ha5A_, 0.9886, 0.79, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
132, d4fs4B_, 0.9886, 0.90, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
133, d4gidB_, 0.9884, 0.71, 1.000, 387, 374, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
134, d3n4lA_, 0.9884, 0.61, 0.997, 375, 373, BACE-1 IN COMPLEX WITH ELN380842
135, d4gidD_, 0.9882, 0.71, 1.000, 387, 374, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
136, d2fdpC_, 0.9882, 0.46, 1.000, 374, 372, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
137, d1ym4A_, 0.9881, 0.83, 1.000, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
138, d2zhrB_, 0.9877, 0.47, 1.000, 385, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
139, d3hvgA_, 0.9871, 0.87, 1.000, 379, 375, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
140, d3l5cB_, 0.9868, 0.68, 1.000, 387, 373, STRUCTURE OF BACE BOUND TO SCH723871
141, d2oahA_, 0.9864, 0.87, 0.995, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
142, d4gidA_, 0.9862, 0.82, 1.000, 387, 374, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
143, d4i0fA1, 0.9861, 0.91, 0.997, 386, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
144, d3lnkB_, 0.9858, 0.59, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH743813
145, d3vf3A_, 0.9855, 0.98, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BQQ711
146, d4d88A_, 0.9853, 0.99, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXQ490
147, d4gmiA_, 0.9850, 1.00, 1.000, 380, 375, BACE-1 IN COMPLEX WITH HEA-TYPE MACROCYCLIC INHIBITOR MV078571
148, d3ixjA_, 0.9850, 0.50, 1.000, 373, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
149, d4r91B_, 0.9849, 0.64, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
150, d3udkA1, 0.9849, 0.86, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 6
151, d3ixkA_, 0.9849, 0.51, 1.000, 373, 371, POTENT BETA-SECRETASE 1 INHIBITOR
152, d3i25A_, 0.9849, 0.51, 1.000, 373, 371, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
153, d2ntrA_, 0.9849, 0.99, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
154, d3lnkA_, 0.9848, 0.63, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH743813
155, d4r93B_, 0.9847, 0.65, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
156, d3veuA_, 0.9847, 1.04, 1.000, 380, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-AVI326
157, d3n4lB_, 0.9847, 0.65, 0.995, 375, 372, BACE-1 IN COMPLEX WITH ELN380842
158, d1ym4C_, 0.9847, 0.94, 1.000, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
159, d4hztA1, 0.9846, 0.96, 0.997, 386, 375, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
160, d4r95B_, 0.9845, 0.66, 1.000, 386, 372, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
161, d4ha5B_, 0.9845, 0.66, 1.000, 386, 372, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
162, d3udhA1, 0.9845, 0.87, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 1
163, d3l5bB_, 0.9844, 0.67, 1.000, 386, 372, STRUCTURE OF BACE BOUND TO SCH713601
164, d4frsB_, 0.9843, 0.67, 1.000, 387, 372, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
165, d3u6aB_, 0.9842, 0.98, 1.000, 386, 375, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
166, d3l5eB_, 0.9842, 0.67, 1.000, 386, 372, STRUCTURE OF BACE BOUND TO SCH736062
167, d3udrA1, 0.9841, 0.88, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14
168, d3udmA1, 0.9841, 0.88, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 8
169, d3kn0A_, 0.9841, 0.66, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH708236
170, d4r8yB_, 0.9840, 0.69, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
171, d3udpA1, 0.9840, 0.88, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12
172, d4r92B_, 0.9839, 0.68, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
173, d4lc7A1, 0.9839, 0.99, 1.000, 396, 375, AMINOOXAZOLINE INHIBITOR OF BACE-1
174, d3udyA1, 0.9839, 0.89, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 11
175, d4r91A_, 0.9838, 0.68, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
176, d3udjA1, 0.9838, 0.90, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 5
177, d4r95A_, 0.9837, 0.69, 1.000, 387, 372, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
178, d4d89A_, 0.9837, 1.08, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A SOAKING EXPERIMENT
179, d3l5cA_, 0.9836, 0.68, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH723871
180, d4r93A_, 0.9835, 0.70, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
181, d4r92A_, 0.9835, 0.69, 1.000, 388, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
182, d3udqA1, 0.9835, 0.91, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 13
183, d3l5bA_, 0.9835, 0.69, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH713601
184, d4wy1A1, 0.9834, 0.91, 1.000, 388, 374, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 24B
185, d4i0eA1, 0.9833, 1.01, 0.997, 386, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
186, d4h1eB_, 0.9833, 0.70, 1.000, 387, 372, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
187, d3u6aC1, 0.9833, 0.99, 1.000, 383, 375, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
188, d3i25C_, 0.9832, 0.59, 0.995, 373, 371, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
189, d4pzwA1, 0.9831, 1.01, 1.000, 391, 375, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
190, d1ym4B_, 0.9831, 1.04, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
191, d4pzxA1, 0.9830, 1.02, 1.000, 394, 375, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
192, d4frsA_, 0.9829, 0.72, 1.000, 386, 372, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
193, d3udnA1, 0.9829, 0.92, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 9
194, d4r8yA_, 0.9828, 0.73, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
195, d4h3iA_, 0.9828, 0.71, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
196, d3n4lC_, 0.9828, 0.83, 0.995, 375, 373, BACE-1 IN COMPLEX WITH ELN380842
197, d3duyC_, 0.9828, 0.63, 1.000, 374, 371, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
198, d4jpeA1, 0.9827, 1.03, 1.000, 396, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
199, d4i0gA1, 0.9827, 1.03, 0.997, 386, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
200, d4fm7A1, 0.9827, 0.94, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14G
201, d2q11B_, 0.9826, 1.04, 0.992, 388, 375, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
202, d3iviB_, 0.9824, 0.48, 1.000, 378, 370, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
203, d4h1eA_, 0.9823, 0.74, 1.000, 386, 372, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
204, d4jpcA1, 0.9822, 1.04, 1.000, 396, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
205, d4dpfA_, 0.9822, 1.00, 1.000, 375, 374, BACE-1 IN COMPLEX WITH A HEA-MACROCYCLIC TYPE INHIBITOR
206, d4fm8A1, 0.9821, 0.95, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12A
207, d2qzkA_, 0.9820, 1.09, 0.995, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
208, d4i0hA_, 0.9818, 0.53, 1.000, 374, 370, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
209, d2zjmA_, 0.9817, 1.09, 0.995, 377, 375, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
210, d4j0zA_, 0.9816, 1.07, 0.997, 381, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S5R)-2-AMINO-5-FLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
211, d4i11A1, 0.9815, 1.07, 0.997, 390, 375, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES.
212, d3vg1A_, 0.9815, 1.14, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A SOAKING EXPERIMENT
213, d2is0A_, 0.9814, 1.10, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
214, d2irzA_, 0.9814, 1.11, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
215, d4i0zA1, 0.9813, 1.00, 0.997, 384, 374, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
216, d3k5fA_, 0.9813, 0.71, 0.997, 373, 371, HUMAN BACE-1 COMPLEX WITH AYH011
217, d4j17A_, 0.9812, 1.07, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-DIFLUOROMETHYL-56-DIHYDRO-4H-[1 3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
218, d2q11C_, 0.9812, 1.08, 0.992, 388, 375, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
219, d2b8lA_, 0.9812, 1.11, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
220, d4jp9A1, 0.9811, 1.09, 1.000, 396, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
221, d3l5dA_, 0.9811, 1.09, 1.000, 396, 375, STRUCTURE OF BACE BOUND TO SCH723873
222, d2q11A_, 0.9811, 0.67, 1.000, 386, 371, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
223, d4j0vA_, 0.9810, 1.09, 0.989, 388, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
224, d4j0yA_, 0.9809, 1.09, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5S)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
225, d4i10A1, 0.9809, 1.09, 0.997, 379, 375, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
226, d4j1eA_, 0.9808, 1.02, 0.997, 384, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
227, d4i0dA1, 0.9808, 1.09, 0.997, 379, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
228, d3ixkB_, 0.9806, 0.91, 1.000, 380, 373, POTENT BETA-SECRETASE 1 INHIBITOR
229, d3ixjB_, 0.9806, 0.73, 1.000, 373, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
230, d3i25B_, 0.9805, 0.73, 1.000, 373, 371, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
231, d4rrsA1, 0.9804, 0.74, 1.000, 373, 371, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
232, d3ckpC_, 0.9804, 1.02, 0.997, 387, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
233, d2fdpA_, 0.9804, 0.91, 0.995, 377, 373, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
234, d5f01A_, 0.9803, 0.73, 1.000, 373, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR2SR)-2-((R)-2-AMINO- 55-DIFLUORO-4-METHYL-56-DIHYDRO-4H-13-OXAZIN-4-YL)-N-(3- CHLOROQUINOLIN-8-YL)CYCLOPROPANECARBOXAMIDE
235, d4n00A1, 0.9802, 1.11, 0.997, 384, 375, DISCOVERY OF 7-THP CHROMANS: BACE1 INHIBITORS THAT REDUCE A-BETA IN THE CNS
236, d4ke0A_, 0.9802, 1.03, 0.997, 387, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
237, d3iviC_, 0.9801, 0.45, 1.000, 375, 369, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
238, d3ckrC_, 0.9801, 0.46, 1.000, 373, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
239, d2p8hA_, 0.9801, 0.92, 0.997, 377, 373, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
240, d4exgA_, 0.9799, 1.16, 0.995, 379, 375, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
241, d4b00A_, 0.9799, 0.99, 1.000, 377, 373, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND (R)-41)
242, d3duyB_, 0.9799, 1.08, 1.000, 375, 374, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
243, d2hizA1, 0.9799, 0.51, 0.997, 370, 369, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
244, d4rrnA1, 0.9798, 0.50, 1.000, 371, 369, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
245, d3zmgA_, 0.9798, 1.05, 0.997, 387, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
246, d2wjoA_, 0.9798, 1.12, 0.997, 385, 375, HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H- QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
247, d2va7A_, 0.9798, 1.01, 1.000, 380, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
248, d2p83A1, 0.9798, 1.03, 1.000, 374, 374, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
249, d4rroA1, 0.9797, 0.51, 1.000, 371, 369, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
250, d4j0tA_, 0.9797, 1.05, 0.997, 387, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-55-DIFLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
251, d5t1uA_, 0.9796, 1.12, 0.997, 381, 375, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
252, d4b77A_, 0.9796, 1.12, 1.000, 380, 375, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
253, d4ke0B_, 0.9795, 1.08, 1.000, 376, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
254, d4ewoA_, 0.9795, 0.76, 1.000, 374, 371, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
255, d4i0jA1, 0.9794, 1.00, 1.000, 377, 373, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
256, d4r5nA1, 0.9793, 0.65, 0.997, 381, 370, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
257, d4dpiA_, 0.9793, 1.07, 0.997, 387, 374, BACE-1 IN COMPLEX WITH HEA-MACROCYCLIC INHIBITOR MV078512
258, d4k8sB_, 0.9792, 1.03, 0.997, 373, 373, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
259, d4k8sA_, 0.9792, 0.50, 1.000, 371, 369, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
260, d3duyA_, 0.9792, 0.51, 1.000, 371, 369, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
261, d3ckpB_, 0.9792, 0.35, 1.000, 370, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
262, d5ezzA_, 0.9791, 1.07, 0.997, 376, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE
263, d4di2B_, 0.9791, 1.20, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
264, d4i0iA_, 0.9790, 0.87, 1.000, 375, 372, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
265, d4b72A_, 0.9790, 0.54, 1.000, 372, 369, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
266, d3nshA_, 0.9790, 1.11, 1.000, 376, 374, BACE-1 IN COMPLEX WITH ELN475957
267, d4di2A_, 0.9788, 0.54, 1.000, 372, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
268, d4azyA_, 0.9787, 0.55, 1.000, 375, 369, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND 10)
269, d3iviA_, 0.9787, 1.11, 0.997, 375, 374, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
270, d5i3wA_, 0.9785, 0.68, 1.000, 380, 370, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE INHIBITOR 2
271, d4b1eA_, 0.9785, 1.08, 0.997, 377, 374, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
272, d3ckrB_, 0.9784, 1.13, 1.000, 375, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
273, d2va6A_, 0.9784, 1.08, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24
274, d2ohsA_, 0.9783, 1.08, 1.000, 376, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
275, d3tpjA_, 0.9782, 1.07, 1.000, 374, 374, APO STRUCTURE OF BACE1
276, d4ke0C_, 0.9781, 0.87, 0.995, 377, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
277, d4k9hB_, 0.9781, 0.56, 1.000, 372, 369, BACE-1 INHIBITOR COMPLEX
278, d4j1fA_, 0.9779, 0.42, 1.000, 369, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
279, d3ckpA_, 0.9776, 0.90, 0.989, 376, 372, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
280, d2wf1A_, 0.9775, 0.81, 1.000, 379, 371, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
281, d4i0iB_, 0.9774, 0.99, 0.989, 374, 372, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
282, d3nshB_, 0.9774, 0.46, 1.000, 376, 368, BACE-1 IN COMPLEX WITH ELN475957
283, d2wf2A_, 0.9774, 0.46, 1.000, 376, 368, HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3478-TETRAHYDRO-1H6H-(125) THIADIAZEPINO(543-DE)QUINOXALINE-10-CARBOXAMIDE 22- DIOXIDE
284, d3ixkC_, 0.9773, 1.00, 0.989, 374, 372, POTENT BETA-SECRETASE 1 INHIBITOR
285, d3ivhA_, 0.9773, 0.64, 1.000, 371, 369, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
286, d2ohuA_, 0.9773, 0.62, 1.000, 379, 369, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B
287, d2ohkA_, 0.9772, 1.14, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1- AMINO-ISOQUINOLINE
288, d4b1dA_, 0.9771, 1.10, 1.000, 377, 374, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
289, d3ixjC_, 0.9771, 1.17, 1.000, 376, 374, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
290, d3ckrA_, 0.9771, 0.65, 1.000, 371, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
291, d4b1cA_, 0.9770, 0.83, 1.000, 379, 371, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
292, d2vnnA_, 0.9770, 0.98, 0.997, 375, 372, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
293, d2wf3A_, 0.9769, 1.00, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-1-METHYL-1345-TETRAHYDRO-21- BENZOTHIAZEPINE-8-CARBOXAMIDE 22-DIOXIDE
294, d2vieA_, 0.9769, 1.01, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-1-BENZYL-2-HYDROXY- 3-((115-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2- OXOPYRROLIDIN-1-YL)BENZAMIDE
295, d1w51A_, 0.9769, 1.02, 0.989, 373, 372, BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON- PEPTIDIC INHIBITOR
296, d4fcoA_, 0.9767, 0.83, 0.997, 374, 371, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
297, d2hizB1, 0.9767, 0.97, 0.995, 374, 372, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
298, d4k9hA_, 0.9766, 0.53, 1.000, 371, 368, BACE-1 INHIBITOR COMPLEX
299, d2vijA_, 0.9766, 0.51, 1.000, 370, 368, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1234-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
300, d2va5A_, 0.9766, 1.01, 0.989, 373, 372, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
301, d2ohqA_, 0.9765, 1.14, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
302, d2vnmA_, 0.9764, 1.15, 1.000, 377, 374, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
303, d4di2C_, 0.9763, 1.03, 0.989, 374, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
304, d2p83B1, 0.9763, 0.54, 1.000, 371, 368, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
305, d3mskA_, 0.9762, 0.55, 1.000, 371, 368, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
306, d2viyA_, 0.9762, 1.14, 1.000, 377, 374, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
307, d4ivsA_, 0.9761, 1.08, 0.987, 372, 372, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
308, d3tppA_, 0.9761, 0.86, 0.995, 373, 371, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
309, d2xfiA_, 0.9761, 0.98, 0.995, 375, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
310, d2ohlA_, 0.9761, 1.07, 0.987, 372, 372, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE
311, d1w50A_, 0.9761, 1.15, 1.000, 377, 374, APO STRUCTURE OF BACE (BETA SECRETASE)
312, d4j0pA_, 0.9759, 1.16, 1.000, 377, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-METHYL-56-DIHYDRO-4H-[13]OXAZIN- 4-YL)-4-FLUORO-PHENYL]-AMIDE
313, d2ohnA_, 0.9759, 0.97, 0.995, 376, 372, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE
314, d2ohmA_, 0.9757, 1.17, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-23-DIAMINE
315, d3dm6A_, 0.9756, 1.16, 1.000, 377, 374, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
316, d2hizC1, 0.9756, 0.57, 0.997, 369, 368, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
317, d4ivtA_, 0.9755, 0.72, 1.000, 372, 369, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
318, d2zjjA_, 0.9755, 0.87, 0.995, 375, 371, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)- AMIDE
319, d4i0hB_, 0.9754, 0.68, 0.992, 370, 369, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
320, d2xfkA_, 0.9754, 0.60, 1.000, 375, 368, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE
321, d2wezA_, 0.9754, 0.97, 0.989, 371, 371, HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE
322, d2wf4A_, 0.9753, 1.09, 0.987, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO- 1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)- 1346-TETRAHYDRO(12)THIAZEPINO(543-CD)INDOLE-8- CARBOXAMIDE 22-DIOXIDE
323, d2p83C1, 0.9752, 1.09, 0.987, 372, 372, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
324, d2wf0A_, 0.9751, 0.74, 1.000, 372, 369, HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
325, d4b70A_, 0.9750, 1.10, 0.987, 372, 372, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
326, d2ohrA_, 0.9750, 1.07, 1.000, 372, 372, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
327, d4k8sC_, 0.9749, 1.16, 1.000, 377, 374, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
328, d3uquA_, 0.9749, 0.73, 1.000, 371, 369, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
329, d3s2oA_, 0.9749, 0.94, 0.995, 374, 371, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
330, d3msmA_, 0.9749, 1.18, 1.000, 377, 374,  
331, d3uqxA_, 0.9748, 1.18, 1.000, 377, 374, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
332, d2xfjA_, 0.9748, 0.95, 0.995, 375, 371, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
333, d4acuA_, 0.9747, 1.11, 0.987, 373, 372, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14
334, d2iqgA_, 0.9745, 0.97, 0.997, 372, 371, CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE)
335, d2hm1A_, 0.9745, 0.63, 1.000, 375, 368, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2)
336, d3dm6B_, 0.9744, 0.63, 1.000, 375, 368, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
337, d2of0A_, 0.9744, 0.64, 1.000, 368, 368, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
338, d4d85A_, 0.9743, 1.20, 1.000, 377, 374, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BVI151
339, d2vizA_, 0.9742, 0.82, 1.000, 374, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
340, d2qzlA_, 0.9741, 0.92, 0.992, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS
341, d2ohtA_, 0.9741, 0.96, 0.995, 375, 371, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
342, d3u6aA_, 0.9740, 1.23, 1.000, 377, 374, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
343, d2fdpB_, 0.9738, 0.94, 1.000, 374, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
344, d3hvgB_, 0.9737, 0.52, 1.000, 369, 367, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
345, d2vj9A_, 0.9737, 0.77, 1.000, 370, 369, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(CYCLOHEXYLAMINO)- 2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO- 1-PYRROLIDINYL)BENZAMIDE
346, d2ohpA_, 0.9736, 0.92, 0.992, 374, 370, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
347, d2vj6A_, 0.9734, 1.24, 1.000, 377, 374, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
348, d5ezxA_, 0.9733, 0.94, 0.992, 370, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R2R)-2-[(R)-2-AMINO-4- (4-DIFLUOROMETHOXY-PHENYL)-45-DIHYDRO-OXAZOL-4-YL]-CYCLOPROPYL}-(5- CHLORO-PYRIDIN-3-YL)-METHANONE
349, d4k9hC_, 0.9732, 0.88, 0.992, 374, 370, BACE-1 INHIBITOR COMPLEX
350, d2vj7A_, 0.9732, 0.70, 1.000, 370, 368, HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
351, d1tqfA_, 0.9730, 0.94, 0.992, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
352, d2b8vA_, 0.9729, 0.88, 0.995, 371, 370, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L- L000430469
353, d4acxA_, 0.9726, 0.90, 0.995, 373, 370, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23
354, d2ph6A_, 0.9725, 0.94, 0.997, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
355, d4i0iC_, 0.9724, 0.92, 0.995, 371, 370, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
356, d3uflA_, 0.9724, 0.73, 1.000, 376, 368, DISCOVERY OF PYRROLIDINE-BASED B-SECRETASE INHIBITORS: LEAD ADVANCEMENT THROUGH CONFORMATIONAL DESIGN FOR MAINTENANCE OF LIGAND BINDING EFFICIENCY
357, d3r1gB1, 0.9724, 0.90, 1.000, 373, 370, STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE- BINDING ANTIBODY
358, d3nshC_, 0.9724, 1.17, 0.995, 380, 373, BACE-1 IN COMPLEX WITH ELN475957
359, d3exoA_, 0.9724, 0.73, 1.000, 376, 368, CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR
360, d5tolA_, 0.9723, 0.88, 0.995, 373, 370, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N- (3-((4AS7AS)-2-AMINO-44A56-TETRAHYDRO-7AH-FURO[23-D][1 3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE
361, d3msjC_, 0.9723, 1.10, 0.997, 374, 372, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
362, d2q15A_, 0.9721, 1.01, 1.000, 375, 371, STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
363, d3msjA_, 0.9719, 1.10, 0.992, 385, 372, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
364, d4b78A_, 0.9710, 0.93, 1.000, 373, 370, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
365, d3hw1A_, 0.9707, 1.13, 1.000, 372, 371, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
366, d3uqwA_, 0.9706, 0.88, 1.000, 370, 369, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
367, d3dm6C_, 0.9704, 1.06, 0.995, 375, 371, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
368, d5clmA_, 0.9703, 0.57, 1.000, 367, 366, 14-OXAZINE BACE1 INHIBITORS
369, d3hvgC_, 0.9703, 1.05, 1.000, 376, 371, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
370, d2zjkA_, 0.9697, 0.96, 1.000, 373, 370, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
371, d4b05A_, 0.9695, 0.82, 0.997, 371, 368, PRECLINICAL CHARACTERIZATION OF AZD3839 A NOVEL CLINICAL CANDIDATE BACE1 INHIBITOR FOR THE TREATMENT OF ALZHEIMER DISEASE
372, d3h0bC_, 0.9693, 0.96, 0.995, 371, 369, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
373, d2zjkC_, 0.9693, 1.05, 1.000, 373, 370, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
374, d4l7jA_, 0.9689, 0.83, 0.997, 371, 368, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
375, d4i0hC_, 0.9686, 0.74, 1.000, 374, 367, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
376, d3h0bB_, 0.9686, 0.78, 1.000, 374, 367, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
377, d4zpfA_, 0.9684, 1.07, 1.000, 373, 370, BACE1 IN COMPLEX WITH 8-(3-((1-AMINOPROPAN-2-YL)OXY)BENZYL)-4- (CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-138-TRIAZASPIRO[4.5]DEC-3-EN- 2-ONE
378, d3hw1C_, 0.9684, 0.85, 0.995, 371, 368, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
379, d4bfdA_, 0.9682, 1.04, 1.000, 375, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
380, d4l7hA_, 0.9681, 0.97, 0.995, 372, 369, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
381, d4wtuA_, 0.9678, 0.78, 1.000, 374, 367, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3-AZA-4- FLUORO-XANTHENE INHIBITOR 22
382, d3mslA_, 0.9678, 0.86, 1.000, 371, 368, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
383, d3hw1B_, 0.9676, 1.34, 1.000, 377, 374, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
384, d4zpeA_, 0.9675, 0.80, 1.000, 371, 367, BACE1 IN COMPLEX WITH 4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-8-(3- ISOPROPOXYBENZYL)-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
385, d4b0qA_, 0.9674, 0.89, 0.992, 369, 368, LEAD GENERATION OF BACE1 INHIBITORS BY COUPLING NON-AMIDINE NEW WARHEADS TO A KNOWN BINDING SCAFFOLD
386, d3h0bA_, 0.9673, 1.10, 0.995, 369, 369, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
387, d4xxsA_, 0.9671, 1.09, 1.000, 372, 370, CRYSTAL STRUCTURE OF BACE1 WITH A PYRAZOLE-SUBSTITUTED TETRAHYDROPYRAN THIOAMIDINE
388, d4x2lA_, 0.9671, 0.91, 1.000, 376, 368, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 6
389, d2zjkB_, 0.9670, 0.90, 1.000, 371, 368, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
390, d4j1iA_, 0.9668, 0.82, 0.997, 369, 367, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
391, d3zovA_, 0.9668, 0.94, 0.995, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
392, d4bekA_, 0.9666, 0.93, 0.995, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
393, d3rsxA_, 0.9665, 0.94, 0.995, 371, 368, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE
394, d4frjA_, 0.9662, 1.20, 1.000, 375, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 9L
395, d5uyuA_, 0.9661, 0.92, 1.000, 373, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE COMPOUND 12
396, d4friA_, 0.9661, 0.83, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH BIARYLSPIRO AMINOOXAZOLINE 2 6
397, d5t1wA_, 0.9660, 0.94, 1.000, 372, 368, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
398, d5f00A_, 0.9660, 0.93, 1.000, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-CHLORO-8- QUINOLYL)AMINO]PHENYL]-5-METHYL-26-DIHYDRO-14-OXAZIN-3-AMINE
399, d4l7gA_, 0.9655, 0.96, 0.995, 371, 368, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE1)
400, d3msjB_, 0.9655, 0.87, 0.984, 373, 367, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
401, d4wy6A_, 0.9654, 1.04, 1.000, 373, 369, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 36
402, d4zpgA_, 0.9652, 0.96, 1.000, 373, 368, BACE1 IN COMPLEX WITH 8-BENZYL-4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)- 7-METHYL-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
403, d3rthA_, 0.9647, 0.89, 0.992, 369, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(2-(33- DIMETHYLBUT-1-YNYL)PHENYL)QUINOLIN-2-AMINE
404, d4j1cA_, 0.9646, 1.01, 0.997, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-55-DIFLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
405, d3kyrA_, 0.9636, 0.91, 0.997, 371, 367, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
406, d4rcfA_, 0.9632, 0.49, 1.000, 365, 363, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 4- FLUOROXANTHENE INHIBITOR 49
407, d4frkA_, 0.9631, 0.86, 0.997, 370, 366, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 11A
408, d3fktA_, 0.9631, 0.85, 1.000, 369, 366, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR
409, d2zjiA_, 0.9631, 0.86, 0.995, 368, 366, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(26-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
410, d3tprA_, 0.9630, 0.98, 0.995, 370, 367, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
411, d3e3wA_, 0.9630, 0.95, 0.997, 368, 367,  
412, d4j1hA_, 0.9629, 0.86, 0.995, 368, 366, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6R)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
413, d5i3xA_, 0.9625, 0.99, 0.995, 370, 367, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 6
414, d2zhvA_, 0.9621, 1.13, 0.997, 373, 368, CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
415, d4rcdA_, 0.9618, 1.00, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH A 2-AMINOOXAZOLINE 4- AZAXANTHENE INHIBITOR
416, d4dh6A_, 0.9617, 0.80, 1.000, 368, 365, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S3R)- 1-(BENZO[D][13]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDINE]-4 -YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE
417, d2ewyD_, 0.9613, 0.81, 0.997, 367, 365, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
418, d2ewyC_, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
419, d2ewyB_, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
420, d2ewyA_, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
421, d2zhtA_, 0.9609, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
422, d2ph8A_, 0.9607, 1.05, 1.000, 370, 367, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
423, d2zhuA_, 0.9606, 0.73, 0.995, 365, 364, CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
424, d3rviA_, 0.9604, 1.06, 1.000, 370, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 2-((2-AMINO-6-O- TOLYLQUINOLIN-3-YL)METHYL)-N-(CYCLOHEXYLMETHYL)PENTANAMIDE
425, d5i3vA_, 0.9603, 1.05, 0.997, 369, 367, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE COMPOUND 1
426, d3rtmA_, 0.9603, 0.98, 0.997, 370, 366, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
427, d2zhsA_, 0.9602, 1.05, 0.997, 369, 367, CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
428, d3buhA_, 0.9600, 1.06, 1.000, 370, 367, BACE-1 COMPLEXED WITH COMPOUND 4
429, d3braA_, 0.9592, 1.00, 0.995, 370, 366, BACE-1 COMPLEXED WITH COMPOUND 1
430, d4j1kA_, 0.9585, 1.03, 0.995, 370, 366, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6S)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
431, d4i1cA1, 0.9583, 0.95, 0.995, 368, 365, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
432, d3zkqA_, 0.9575, 1.03, 1.000, 373, 366, BACE2 XAPERONE COMPLEX
433, d3s7mA_, 0.9565, 1.55, 0.552, 376, 373, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
434, d3in3A_, 0.9563, 0.81, 1.000, 371, 363, BACE1 WITH COMPOUND 30
435, d3lhgA_, 0.9562, 0.83, 1.000, 370, 363, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 4G
436, d5i3yA_, 0.9559, 0.83, 1.000, 369, 363, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 9
437, d3s7lA_, 0.9557, 1.04, 1.000, 369, 365, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
438, d3igbA_, 0.9548, 0.85, 1.000, 369, 363, BACE-1 WITH COMPOUND 3
439, d3kyrB_, 0.9547, 0.77, 1.000, 369, 362, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
440, d3oozA_, 0.9545, 0.69, 0.983, 363, 361, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 102
441, d3rtnA_, 0.9544, 0.80, 1.000, 368, 362, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2-AMINO-6-O- TOLYLQUINOLIN-3-YL)-N-CYCLOHEXYLPROPANAMIDE
442, d2zjnA_, 0.9540, 1.07, 0.997, 367, 365, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
443, d2zdzA_, 0.9539, 1.06, 0.995, 367, 365, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
444, d3in4A_, 0.9538, 0.97, 1.000, 370, 363, BACE1 WITH COMPOUND 38
445, d3indA_, 0.9532, 0.98, 1.000, 370, 363, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29
446, d3ineA_, 0.9513, 0.84, 1.000, 370, 362, BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34
447, d4dusA_, 0.9502, 0.84, 0.997, 367, 361, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH N-((2S3R)-1-(4- FLUOROPHENYL)-3-HYDROXY-4-((6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDIN]-4 -YL)AMINO) BUTAN-2-YL)ACETAMIDE
448, d4rceA_, 0.9500, 1.00, 0.994, 365, 363, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE INHIBITOR 2
449, d3kyrC_, 0.9494, 0.85, 1.000, 364, 361, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
450, d4xkxA_, 0.9491, 0.55, 1.000, 360, 358, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3- AZAXANTHENE INHIBITOR 28
451, d2qu3A_, 0.9490, 0.89, 0.997, 363, 361, BACE1 WITH COMPOUND 2
452, d3rsvA_, 0.9465, 0.94, 0.997, 368, 361, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (R)-3-(2-AMINO-6- O-TOLYLQUINOLIN-3-YL)-N-((R)-22-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2- METHYLPROPANAMIDE
453, d3ru1A_, 0.9462, 0.98, 0.989, 364, 361, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE
454, d3inhA_, 0.9458, 1.00, 0.978, 363, 361, BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58
455, d4i12A1, 0.9453, 0.82, 1.000, 366, 359, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
456, d4bfbB_, 0.9444, 1.05, 0.994, 368, 361, BACE2 XAPERONE COMPLEX
457, d3zkxA_, 0.9431, 1.69, 0.554, 374, 368, TERNARY BACE2 XAPERONE COMPLEX
458, d3infA_, 0.9431, 1.57, 0.550, 370, 367, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37
459, d4bfbA_, 0.9430, 0.82, 0.997, 367, 358, BACE2 XAPERONE COMPLEX
460, d3vv7A_, 0.9423, 1.56, 0.555, 373, 366, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-6-((1S2R)- 2-(3 -METHOXYBIPHENYL-3-YL)CYCLOPROPYL)-3-METHYLPYRIMIDIN-4(3H)-ONE
461, d3l3aA_, 0.9422, 0.95, 0.997, 361, 359, BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32
462, d3zlqB_, 0.9418, 0.99, 0.997, 365, 359, BACE2 XAPERONE COMPLEX
463, d3wb5A_, 0.9417, 1.77, 0.554, 370, 368, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH (6S)-2-AMINO-36- DIMETHYL-6-[(1R2R)-2-PHENYLCYCLOPROPYL]-3456-TETRAHYDROPYRIMIDIN- 4-ONE
464, d5enkA_, 0.9413, 0.97, 0.997, 361, 359, COMPOUND 18
465, d3l38A_, 0.9408, 0.89, 0.997, 359, 358, BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
466, d5kr8A_, 0.9406, 0.81, 1.000, 364, 357, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-6-(35-DIMETHYL-12-OXAZOL- 4-YL)-4-METHYL-56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1
467, d5ie1A_, 0.9401, 0.92, 0.997, 359, 358, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 3-(2-AMINO-6-(O-TOLYL) QUINOLIN-3-YL)-N-(33-DIMETHYLBUTYL)PROPANAMIDE
468, d5enmA_, 0.9401, 1.07, 0.992, 361, 359, COMPOUND 10
469, d5kqfA_, 0.9398, 0.93, 0.997, 359, 358, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-4-METHYL-6-PYRIMIDIN-5-YL- 56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 12) BOUND TO BACE1
470, d3vv6A_, 0.9393, 0.95, 0.997, 358, 358, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S 2R)-2-PHENYLCYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
471, d2qu2A_, 0.9387, 0.96, 0.997, 360, 358, BACE1 WITH COMPOUND 1
472, d2ze1A_, 0.9374, 0.95, 1.000, 364, 357, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
473, d3wb4A_, 0.9343, 0.91, 0.994, 360, 356, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-36- DIMETHYL-6-(2-PHENYLETHYL)-3456-TETRAHYDROPYRIMIDIN-4-ONE
474, d3zlqA_, 0.9342, 1.02, 0.997, 360, 357, BACE2 XAPERONE COMPLEX
475, d3vv8A_, 0.9342, 1.78, 0.556, 367, 365, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S2R)-2-(3 -METHYLBIPHENYL-4-YL)CYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
476, d3zkmA_, 0.9333, 0.96, 0.997, 358, 356, BACE2 FAB COMPLEX
477, d3bugA_, 0.9331, 2.17, 0.545, 375, 369, BACE-1 COMPLEXED WITH COMPOUND 3
478, d3zkgA_, 0.9330, 0.93, 0.994, 357, 355, BACE2 MUTANT APO STRUCTURE
479, d3zkmB_, 0.9324, 1.47, 0.562, 364, 361, BACE2 FAB COMPLEX
480, d2zjhA_, 0.9319, 2.19, 0.545, 375, 369, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
481, d3zknB_, 0.9317, 0.84, 0.997, 356, 354, BACE2 FAB INHIBITOR COMPLEX
482, d3zkiA_, 0.9315, 2.20, 0.545, 375, 369, BACE2 MUTANT STRUCTURE WITH LIGAND
483, d3bufA_, 0.9307, 1.56, 0.564, 365, 362, BACE-1 COMPLEXED WITH COMPOUND 2
484, d3zknA_, 0.9304, 1.03, 0.994, 359, 355, BACE2 FAB INHIBITOR COMPLEX
485, d4ke1A_, 0.9279, 2.23, 0.545, 375, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 19
486, d4belA_, 0.9248, 0.78, 1.000, 355, 352, BACE2 XAPERONE COMPLEX
487, d3zksA_, 0.9229, 1.32, 0.567, 358, 356, BACE2 XAPERONE COMPLEX WITH INHIBITOR
488, d3zkiB_, 0.9222, 1.47, 0.561, 360, 358, BACE2 MUTANT STRUCTURE WITH LIGAND
489, d3zkgB_, 0.9200, 1.62, 0.565, 361, 359, BACE2 MUTANT APO STRUCTURE
490, d4belB_, 0.9193, 1.52, 0.569, 359, 357, BACE2 XAPERONE COMPLEX
491, d2zjlA_, 0.9013, 1.38, 0.569, 357, 355, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-23-DIMETHOXY-BENZYL)-PIPERIDIN- 4-YL]-4-MERCAPTO-BUTYRAMIDE
492, d2rmpA_, 0.8083, 0.92, 0.994, 344, 343, RMP-PEPSTATIN A COMPLEX
493, d2asiA_, 0.8015, 2.52, 0.201, 358, 333, ASPARTIC PROTEINASE
494, d1mppA_, 0.7986, 2.52, 0.201, 358, 333, X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
495, d1lya.1, 0.7873, 2.52, 0.202, 356, 331, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
496, d1lyb.1, 0.7860, 2.60, 0.217, 357, 332, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
497, d1lya.2, 0.7853, 2.28, 0.292, 338, 319, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
498, d1lyb.2, 0.7846, 2.28, 0.292, 338, 319, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
499, d1fq8A_, 0.7760, 2.32, 0.285, 338, 319, X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81198 BOUND TO SACCHAROPEPSIN
500, d1jxrA_, 0.7754, 2.34, 0.285, 338, 319,  
501, d2jxrA_, 0.7753, 2.35, 0.285, 338, 319, STRUCTURE OF YEAST PROTEINASE A
502, d1fq6A_, 0.7752, 2.13, 0.250, 329, 312, X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133450 BOUND TO SACCHAROPEPSIN
503, d1fq7A_, 0.7750, 2.15, 0.250, 329, 312, X-RAY STRUCTURE OF INHIBITOR CP-72647 BOUND TO SACCHAROPEPSIN
504, d1fq4A_, 0.7750, 2.15, 0.250, 329, 312, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP- 108420 AND YEAST ASPARTIC PROTEINASE A
505, d4aa8A_, 0.7744, 2.15, 0.250, 329, 312, BOVINE CHYMOSIN AT 1.8A RESOLUTION
506, d1fq5A_, 0.7744, 2.16, 0.250, 329, 312, X-RAY STRUCTURE OF A CYCLIC STATINE INHIBITOR PD-129541 BOUND TO YEAST PROTEINASE A
507, d4aucA_, 0.7733, 2.15, 0.250, 329, 312, BOVINE CHYMOSIN IN COMPLEX WITH PEPSTATIN A
508, d1qrpE_, 0.7731, 2.33, 0.252, 323, 313, HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME
509, d1xdhB_, 0.7729, 2.16, 0.250, 329, 312, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
510, d1m43B_, 0.7724, 2.23, 0.256, 323, 312, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
511, d1psoE_, 0.7719, 2.16, 0.273, 326, 311, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
512, d1cziE_, 0.7719, 2.37, 0.232, 329, 315, CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972
513, d1w6iC_, 0.7716, 2.46, 0.228, 331, 316, PLASMEPSIN II-PEPSTATIN A COMPLEX
514, d1psnA_, 0.7714, 2.18, 0.273, 326, 311, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
515, d1xe5B_, 0.7713, 2.47, 0.252, 323, 314, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
516, d1xe6B_, 0.7709, 2.43, 0.232, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
517, d1bimB_, 0.7709, 2.25, 0.269, 326, 312, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
518, d1bilB_, 0.7708, 2.42, 0.232, 329, 315, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
519, d4q1nB_, 0.7703, 2.41, 0.235, 329, 315, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
520, d3ownB_, 0.7702, 2.53, 0.248, 333, 314, POTENT MACROCYCLIC RENIN INHIBITORS
521, d1cmsA_, 0.7702, 2.43, 0.249, 333, 313, THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION
522, d2i4qB1, 0.7701, 2.54, 0.248, 336, 314, HUMAN RENIN/PF02342674 COMPLEX
523, d1me6B_, 0.7700, 2.63, 0.251, 334, 315, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
524, d5vpmB_, 0.7699, 2.39, 0.252, 323, 313, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
525, d5mlgA1, 0.7698, 2.39, 0.252, 323, 313, CRYSTAL STRUCTURE OF RAT PRORENIN
526, d4s1gB_, 0.7698, 2.53, 0.245, 334, 314, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
527, d4gjbB_, 0.7698, 2.46, 0.232, 329, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
528, d1smeB_, 0.7698, 2.66, 0.247, 335, 316, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
529, d1b5f.1, 0.7695, 2.22, 0.256, 362, 312, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
530, d4xx4B_, 0.7694, 2.22, 0.256, 362, 312, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
531, d1f34A_, 0.7694, 2.64, 0.248, 338, 315, CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN
532, d6aprE_, 0.7690, 2.56, 0.248, 335, 314, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
533, d4gj9B_, 0.7689, 2.47, 0.232, 329, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
534, d3d91A1, 0.7688, 2.08, 0.246, 326, 309, HUMAN RENIN IN COMPLEX WITH REMIKIREN
535, d3cmsA_, 0.7687, 2.55, 0.245, 338, 314, ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN
536, d5pepA_, 0.7686, 2.26, 0.270, 325, 311, X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION
537, d5kotB_, 0.7685, 2.38, 0.217, 325, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
538, d4gjcB_, 0.7685, 2.56, 0.248, 335, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
539, d5tmgB_, 0.7684, 2.62, 0.244, 333, 315, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
540, d4gjaB_, 0.7684, 2.39, 0.256, 320, 312, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
541, d4gj8B_, 0.7684, 2.26, 0.270, 326, 311, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
542, d4gj5B_, 0.7684, 2.48, 0.246, 333, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
543, d2il2B_, 0.7684, 2.47, 0.249, 337, 313, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
544, d2ikuB_, 0.7684, 2.47, 0.249, 334, 313, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
545, d3d91B1, 0.7683, 2.48, 0.249, 337, 313, HUMAN RENIN IN COMPLEX WITH REMIKIREN
546, d3aprE_, 0.7683, 2.48, 0.252, 335, 313, BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION
547, d5aprE_, 0.7682, 2.52, 0.248, 331, 314, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
548, d4rz1B_, 0.7682, 2.48, 0.252, 338, 313, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
549, d1flhA_, 0.7682, 2.58, 0.252, 337, 314, CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
550, d5vpmA_, 0.7681, 2.71, 0.250, 336, 316, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
551, d4rygB_, 0.7681, 2.39, 0.217, 325, 313, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
552, d4gjbA_, 0.7681, 2.39, 0.217, 325, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
553, d4cmsA_, 0.7681, 2.48, 0.246, 336, 313, X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN
554, d3utlA_, 0.7681, 2.26, 0.267, 326, 311, HUMAN PEPSIN 3B
555, d3oqkB_, 0.7681, 2.64, 0.248, 334, 315, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
556, d1uh7A_, 0.7681, 2.48, 0.249, 337, 313, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6
557, d5v8vB_, 0.7680, 2.48, 0.252, 335, 313, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
558, d4gj9A_, 0.7680, 2.38, 0.260, 320, 312, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
559, d5v8vA_, 0.7679, 2.27, 0.267, 326, 311, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
560, d5kosB_, 0.7679, 2.48, 0.249, 337, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
561, d1uh9A_, 0.7678, 2.40, 0.217, 325, 313, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0
562, d4aprE_, 0.7677, 2.40, 0.217, 325, 313, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
563, d3oqfB_, 0.7677, 2.57, 0.252, 337, 314, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
564, d1psaB_, 0.7677, 2.60, 0.252, 333, 314, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
565, d3q3tA_, 0.7676, 2.58, 0.252, 337, 314, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
566, d3ootB_, 0.7676, 2.48, 0.246, 332, 313, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
567, d1psaA_, 0.7676, 2.40, 0.217, 325, 313, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
568, d4xx3B_, 0.7675, 2.40, 0.217, 325, 313, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
569, d2aprA_, 0.7675, 2.48, 0.249, 337, 313, STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS
570, d1hrnB_, 0.7675, 2.28, 0.270, 326, 311, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
571, d4gjdB_, 0.7674, 2.60, 0.252, 337, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
572, d3q5hB_, 0.7673, 2.57, 0.248, 337, 314, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
573, d3vyfB_, 0.7672, 2.34, 0.266, 326, 312, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
574, d3vydB_, 0.7672, 2.48, 0.249, 338, 313, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
575, d1uh8A_, 0.7672, 2.40, 0.217, 325, 313, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0
576, d4gjaA_, 0.7671, 2.50, 0.246, 333, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
577, d1bilA_, 0.7670, 2.50, 0.249, 337, 313, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
578, d4rycB_, 0.7669, 2.58, 0.252, 338, 314, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
579, d3q3tB_, 0.7669, 2.50, 0.249, 335, 313, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
580, d1yx9A_, 0.7669, 2.50, 0.249, 337, 313, EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN
581, d1bbsB_, 0.7669, 2.41, 0.217, 325, 313, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
582, d1bbsA_, 0.7669, 2.67, 0.244, 337, 315, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
583, d4q1nA_, 0.7668, 2.64, 0.248, 334, 315, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
584, d3vyeB_, 0.7668, 2.51, 0.249, 336, 313, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
585, d4gjcA_, 0.7667, 2.67, 0.254, 333, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
586, d4gj8A_, 0.7667, 2.30, 0.270, 326, 311, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
587, d4gj5A_, 0.7667, 2.55, 0.248, 331, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
588, d3ownA_, 0.7667, 2.55, 0.248, 331, 314, POTENT MACROCYCLIC RENIN INHIBITORS
589, d4gj7B_, 0.7666, 2.67, 0.244, 336, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
590, d3vyeA_, 0.7666, 2.51, 0.249, 335, 313, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
591, d3q5hA_, 0.7666, 2.68, 0.244, 337, 315, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
592, d2ikoA_, 0.7666, 2.62, 0.252, 334, 314, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
593, d4rz1A_, 0.7665, 2.57, 0.248, 332, 314, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
594, d1ls5B_, 0.7665, 2.66, 0.248, 334, 315, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
595, d2il2A_, 0.7664, 2.50, 0.249, 336, 313, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
596, d4pyvB_, 0.7663, 2.64, 0.248, 335, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
597, d3km4A_, 0.7663, 2.66, 0.248, 337, 315, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
598, d1rneA_, 0.7663, 2.69, 0.244, 338, 315, THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
599, d1bimA_, 0.7663, 2.69, 0.244, 336, 315, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
600, d3sfcB_, 0.7662, 2.50, 0.229, 328, 315, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
601, d2v16O_, 0.7662, 2.61, 0.245, 338, 314, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
602, d2ikuA_, 0.7662, 2.50, 0.249, 334, 313, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
603, d5tmkB_, 0.7661, 2.53, 0.252, 337, 313, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
604, d4pyvA_, 0.7661, 2.83, 0.244, 329, 316, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
605, d3q4bB_, 0.7661, 2.65, 0.248, 334, 315, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
606, d3q4bA_, 0.7661, 2.54, 0.249, 340, 313, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
607, d1hrnA_, 0.7661, 2.51, 0.249, 331, 313, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
608, d3vydA_, 0.7659, 2.71, 0.244, 337, 315, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
609, d3gw5A_, 0.7659, 2.41, 0.248, 330, 311, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
610, d2g1sB_, 0.7659, 2.66, 0.248, 335, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
611, d4rygA_, 0.7658, 2.56, 0.248, 337, 314, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
612, d2v10O_, 0.7658, 2.67, 0.248, 337, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
613, d2i4qA1, 0.7658, 2.71, 0.244, 334, 315, HUMAN RENIN/PF02342674 COMPLEX
614, d2g1yB_, 0.7658, 2.65, 0.248, 337, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
615, d2g1nB_, 0.7658, 2.62, 0.252, 337, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
616, d3pepA_, 0.7657, 2.31, 0.252, 333, 310, REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
617, d2g1rB_, 0.7657, 2.69, 0.244, 336, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
618, d1am5A_, 0.7657, 2.51, 0.249, 331, 313, THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)
619, d4gjdA_, 0.7656, 2.53, 0.246, 334, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
620, d2g21B_, 0.7656, 2.32, 0.248, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
621, d1jgfB_, 0.7656, 2.31, 0.248, 333, 310,  
622, d1fmuA_, 0.7655, 2.31, 0.267, 326, 311, STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.
623, d3km4B_, 0.7654, 2.32, 0.248, 333, 310, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
624, d1smrG_, 0.7654, 2.21, 0.274, 324, 310, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
625, d1smrE_, 0.7654, 2.67, 0.248, 335, 315, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
626, d1smrC_, 0.7654, 2.31, 0.252, 329, 310, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
627, d1smrA_, 0.7654, 2.50, 0.232, 328, 315, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
628, d1fmxA_, 0.7654, 2.17, 0.256, 322, 309, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
629, d4xx4A_, 0.7653, 2.63, 0.252, 333, 314, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
630, d3vswB_, 0.7653, 2.46, 0.252, 331, 313, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
631, d3gw5B_, 0.7653, 2.46, 0.252, 331, 313, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
632, d2g1oB_, 0.7653, 2.46, 0.252, 331, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
633, d2g24B_, 0.7652, 2.46, 0.252, 331, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
634, d2g20B_, 0.7652, 2.10, 0.254, 325, 307, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
635, d1dp5A_, 0.7652, 2.67, 0.248, 339, 315, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR
636, d4gj6B_, 0.7651, 2.54, 0.249, 340, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
637, d3vsxB_, 0.7651, 2.62, 0.252, 332, 314, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
638, d3vsxA_, 0.7651, 2.33, 0.248, 333, 310, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
639, d2v11O_, 0.7651, 2.32, 0.252, 329, 310, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
640, d1xdhA_, 0.7651, 2.33, 0.252, 333, 310, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
641, d1g0vA_, 0.7651, 2.39, 0.264, 329, 311, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT MVV
642, d4xx3A_, 0.7650, 2.39, 0.264, 329, 311, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
643, d3sfcA_, 0.7649, 2.56, 0.248, 333, 314, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
644, d3g72A_, 0.7649, 2.56, 0.249, 340, 313, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
645, d2g22B_, 0.7648, 2.65, 0.248, 340, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
646, d4s1gA_, 0.7647, 2.62, 0.248, 331, 314, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
647, d2g1yA_, 0.7647, 2.53, 0.235, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
648, d1b5f.2, 0.7647, 2.35, 0.264, 329, 311, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
649, d3vswA_, 0.7646, 2.68, 0.248, 339, 315, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
650, d2g1sA_, 0.7646, 2.67, 0.248, 340, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
651, d2g1rA_, 0.7646, 2.68, 0.248, 333, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
652, d1w6iA_, 0.7646, 2.34, 0.252, 333, 310, PLASMEPSIN II-PEPSTATIN A COMPLEX
653, d3vyfA_, 0.7645, 2.72, 0.244, 339, 315, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
654, d3vucB_, 0.7645, 2.52, 0.247, 333, 312, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
655, d2v0zO_, 0.7645, 2.12, 0.253, 325, 308, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
656, d3oqfA_, 0.7644, 2.69, 0.248, 340, 315, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
657, d1m43A_, 0.7644, 2.52, 0.247, 333, 312, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
658, d2g21A_, 0.7643, 2.53, 0.247, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
659, d1me6A_, 0.7643, 2.54, 0.235, 329, 315, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
660, d1dpjA_, 0.7643, 2.68, 0.248, 336, 314, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR
661, d3oqkA_, 0.7642, 2.55, 0.252, 338, 313, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
662, d2v0zC_, 0.7642, 2.58, 0.246, 336, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
663, d4gj6A_, 0.7641, 2.69, 0.248, 337, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
664, d4ckuB_, 0.7641, 2.61, 0.228, 331, 316, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
665, d4gj7A_, 0.7640, 2.52, 0.247, 329, 312, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
666, d3ootA_, 0.7640, 2.55, 0.232, 329, 315, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
667, d1w6hA_, 0.7640, 2.40, 0.264, 329, 311, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
668, d2qzxB_, 0.7639, 2.73, 0.244, 337, 315, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
669, d2g24A_, 0.7639, 2.73, 0.244, 338, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
670, d1jgfA_, 0.7639, 2.59, 0.248, 333, 314,  
671, d1fmxB_, 0.7639, 2.42, 0.230, 327, 313, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
672, d3g72B_, 0.7638, 2.69, 0.248, 335, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
673, d4rycA_, 0.7637, 2.64, 0.252, 337, 314, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
674, d3k1wA1, 0.7637, 2.29, 0.232, 325, 311, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
675, d5tmgA_, 0.7636, 2.48, 0.234, 342, 312, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
676, d2fs4A_, 0.7636, 2.54, 0.247, 329, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
677, d2bksA_, 0.7636, 2.57, 0.229, 328, 315, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
678, d2g26A_, 0.7635, 2.14, 0.257, 325, 307, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
679, d2g22A_, 0.7635, 2.55, 0.252, 336, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
680, d2g1oA_, 0.7634, 2.70, 0.248, 336, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
681, d2g1nA_, 0.7633, 2.72, 0.248, 332, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
682, d1xe6A_, 0.7633, 2.70, 0.248, 334, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
683, d4pepA_, 0.7632, 2.54, 0.247, 329, 312, THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION
684, d1xe5A_, 0.7632, 2.54, 0.247, 329, 312, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
685, d3vucA_, 0.7631, 2.53, 0.247, 329, 312, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
686, d3g70A1, 0.7631, 2.55, 0.247, 333, 312, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
687, d2r9bA_, 0.7630, 2.52, 0.250, 333, 312, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
688, d3g70B1, 0.7629, 2.51, 0.250, 333, 312, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
689, d4ckuF_, 0.7628, 2.56, 0.232, 329, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
690, d3k1wB1, 0.7628, 2.32, 0.271, 325, 310, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
691, d1smeA_, 0.7628, 2.57, 0.232, 329, 315, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
692, d1lf3A_, 0.7627, 2.72, 0.248, 340, 315, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
693, d5kotA_, 0.7626, 2.62, 0.248, 333, 314, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
694, d2v10C_, 0.7625, 2.57, 0.235, 329, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
695, d2v11C_, 0.7624, 2.57, 0.252, 336, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
696, d2v16C_, 0.7622, 2.57, 0.222, 329, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
697, d1w6hB_, 0.7619, 2.57, 0.252, 336, 313, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
698, d3g6zB1, 0.7616, 2.60, 0.232, 329, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
699, d3g6zA1, 0.7616, 2.66, 0.228, 331, 316, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
700, d2v13A_, 0.7615, 2.72, 0.248, 332, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 7
701, d2r9bB_, 0.7613, 2.73, 0.248, 333, 315, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
702, d2qzxA_, 0.7613, 2.65, 0.248, 333, 314, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
703, d1ls5A_, 0.7613, 2.74, 0.248, 333, 315, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
704, d1qs8B_, 0.7611, 2.36, 0.232, 325, 311, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
705, d2g20A_, 0.7608, 2.65, 0.245, 333, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
706, d2bktB_, 0.7608, 2.69, 0.248, 336, 314, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
707, d5sy2A_, 0.7602, 2.76, 0.248, 329, 315, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
708, d5koqA_, 0.7602, 2.62, 0.235, 329, 315, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
709, d2g27B_, 0.7602, 2.52, 0.237, 342, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
710, d1avf.2, 0.7602, 2.52, 0.237, 342, 312, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
711, d2bktA_, 0.7601, 2.60, 0.229, 328, 315, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
712, d5tmkA_, 0.7593, 2.60, 0.229, 328, 314, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
713, d4ckuD_, 0.7587, 2.59, 0.247, 333, 312, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
714, d1wkrA_, 0.7587, 2.65, 0.249, 329, 313, CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS
715, d1lf2A_, 0.7583, 2.71, 0.246, 335, 313, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
716, d2bjuA1, 0.7581, 2.65, 0.246, 335, 313, PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR
717, d2renA_, 0.7579, 2.61, 0.250, 328, 312, STRUCTURE OF RECOMBINANT HUMAN RENIN A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS AT 2.5 ANGSTROMS RESOLUTION
718, d2g27A_, 0.7579, 2.42, 0.250, 344, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
719, d5koqB_, 0.7578, 2.61, 0.252, 329, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
720, d3f9qA_, 0.7578, 2.72, 0.246, 333, 313, RE-REFINEMENT OF UNCOMPLEXED PLASMEPSIN II FROM PLASMODIUM FALCIPARUM.
721, d5kosA_, 0.7577, 2.27, 0.233, 323, 309, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
722, d2g26B_, 0.7573, 2.85, 0.242, 340, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
723, d1leeA_, 0.7572, 2.85, 0.242, 340, 314, CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
724, d3emyA_, 0.7561, 2.68, 0.232, 329, 315, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN A
725, d2fs4B_, 0.7561, 2.65, 0.232, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
726, d2bksB_, 0.7561, 2.31, 0.248, 320, 307, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
727, d4y6mA_, 0.7559, 2.67, 0.249, 328, 313, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
728, d1qdmA2, 0.7558, 2.49, 0.243, 333, 309, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
729, d1qs8A_, 0.7556, 2.42, 0.235, 325, 311, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
730, d1epmE_, 0.7555, 2.72, 0.249, 331, 313, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
731, d4er2E_, 0.7551, 2.47, 0.252, 329, 310, THE ACTIVE SITE OF ASPARTIC PROTEINASES
732, d4er1E_, 0.7549, 2.71, 0.229, 331, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
733, d1epqE_, 0.7549, 2.63, 0.226, 328, 314, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-133 450 (SOT PHE GLY+SCC GCL)
734, d1eppE_, 0.7548, 2.50, 0.252, 329, 310, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130 693 (MAS PHE LYS+MTF STA MBA)
735, d1avf.1, 0.7548, 2.50, 0.252, 329, 310, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
736, d1epnE_, 0.7547, 2.80, 0.222, 329, 315, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
737, d3er5E_, 0.7546, 2.40, 0.279, 332, 308, THE ACTIVE SITE OF ASPARTIC PROTEINASES
738, d1entE_, 0.7545, 2.67, 0.230, 327, 313, X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN
739, d4y6mB_, 0.7544, 2.71, 0.251, 330, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
740, d1eedP_, 0.7544, 2.72, 0.251, 330, 315, X-RAY CRYSTALLOGRAPHIC ANALYSIS OF INHIBITION OF ENDOTHIAPEPSIN BY CYCLOHEXYL RENIN INHIBITORS
741, d2er7E_, 0.7543, 2.72, 0.251, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION
742, d1er8E_, 0.7542, 2.72, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
743, d1ppmE_, 0.7540, 2.72, 0.251, 330, 315, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
744, d1lf4A_, 0.7540, 2.42, 0.248, 341, 310, STRUCTURE OF PLASMEPSIN II
745, d1apuE_, 0.7540, 2.72, 0.251, 330, 315, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
746, d3er3E_, 0.7539, 2.73, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
747, d2webA_, 0.7539, 2.72, 0.251, 330, 315, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE SODIUM SALT
748, d2er0E_, 0.7539, 2.75, 0.226, 328, 314, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES
749, d1bxoA_, 0.7539, 2.73, 0.251, 330, 315, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3- METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE
750, d5er2E_, 0.7538, 2.73, 0.251, 330, 315, HIGH-RESOLUTION X-RAY DIFFRACTION STUDY OF THE COMPLEX BETWEEN ENDOTHIAPEPSIN AND AN OLIGOPEPTIDE INHIBITOR. THE ANALYSIS OF THE INHIBITOR BINDING AND DESCRIPTION OF THE RIGID BODY SHIFT IN THE ENZYME
751, d2psgA_, 0.7538, 2.73, 0.251, 330, 315, REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION
752, d1apvE_, 0.7537, 2.69, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
753, d1aptE_, 0.7537, 2.44, 0.235, 325, 310, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
754, d1bxqA_, 0.7536, 2.69, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.
755, d4ckuC_, 0.7535, 2.74, 0.251, 330, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
756, d4ckuA_, 0.7535, 2.69, 0.228, 323, 312, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
757, d1ppkE_, 0.7535, 2.74, 0.251, 330, 315, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES
758, d1apwE_, 0.7535, 2.69, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
759, d2wecA_, 0.7533, 2.73, 0.251, 330, 315, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1- NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE SODIUM SALT
760, d4amtA_, 0.7532, 2.50, 0.265, 369, 310, CRYSTAL STRUCTURE AT 2.6A OF HUMAN PRORENIN
761, d1eprE_, 0.7532, 2.69, 0.228, 323, 312, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135 040
762, d3psgA_, 0.7531, 2.69, 0.228, 323, 312, THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN
763, d2igyA_, 0.7530, 2.69, 0.228, 323, 312, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
764, d2wedA_, 0.7529, 2.39, 0.227, 322, 308, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
765, d1pplE_, 0.7529, 2.43, 0.223, 323, 309, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
766, d2igyB_, 0.7527, 2.69, 0.231, 323, 312, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
767, d2ikoB_, 0.7525, 2.70, 0.228, 323, 312, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
768, d4z22B_, 0.7524, 2.70, 0.228, 323, 312, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
769, d3urjA_, 0.7523, 2.49, 0.249, 349, 309, TYPE IV NATIVE ENDOTHIAPEPSIN
770, d3c9xA_, 0.7523, 2.77, 0.251, 329, 315, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE
771, d3urlA_, 0.7522, 2.48, 0.272, 365, 309, ENDOTHIAPEPSIN-DB6 COMPLEX.
772, d1e5oE_, 0.7521, 2.78, 0.226, 329, 314, ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2
773, d4ckuE_, 0.7520, 2.71, 0.228, 323, 312, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
774, d4y6mC_, 0.7519, 2.72, 0.231, 323, 312, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
775, d1qdmB2, 0.7519, 2.85, 0.232, 329, 315, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
776, d1lyw.4, 0.7519, 2.58, 0.247, 332, 308, CATHEPSIN D AT PH 7.5
777, d1eplE_, 0.7519, 2.79, 0.229, 329, 315, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
778, d1epoE_, 0.7518, 2.76, 0.248, 328, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81282 (MOR PHE NLE CHF NME)
779, d2igxA_, 0.7517, 2.67, 0.232, 328, 314, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
780, d2er6E_, 0.7516, 2.76, 0.248, 328, 315, THE STRUCTURE OF A SYNTHETIC PEPSIN INHIBITOR COMPLEXED WITH ENDOTHIAPEPSIN.
781, d1gvxA_, 0.7516, 2.77, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEXED WITH H256
782, d1gktA_, 0.7516, 2.77, 0.245, 330, 314, NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261
783, d2vs2A_, 0.7515, 2.42, 0.227, 322, 308, NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
784, d2jjiA_, 0.7515, 2.84, 0.223, 329, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
785, d3uriA_, 0.7514, 2.50, 0.269, 332, 308, ENDOTHIAPEPSIN-DB5 COMPLEX.
786, d4apeA_, 0.7513, 2.62, 0.297, 336, 310, THE ACTIVE SITE OF ASPARTIC PROTEINASES
787, d3appA_, 0.7513, 2.77, 0.245, 330, 314, STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
788, d1lyw.1, 0.7513, 2.81, 0.251, 330, 315, CATHEPSIN D AT PH 7.5
789, d5er1E_, 0.7512, 2.80, 0.235, 329, 315, A RATIONAL APPROACH TO THE DESIGN OF ANTIHYPERTENSIVES. X-RAY STUDIES OF COMPLEXES BETWEEN ASPARTIC PROTEINASES AND AMINOALCOHOL RENIN INHIBITORS
790, d1lyw.2, 0.7512, 2.77, 0.245, 330, 314, CATHEPSIN D AT PH 7.5
791, d4er4E_, 0.7511, 2.80, 0.251, 328, 315, HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES
792, d2weaA_, 0.7511, 2.77, 0.248, 328, 315, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
793, d1oexA_, 0.7510, 2.79, 0.248, 328, 315, ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261
794, d3wz8A_, 0.7509, 2.79, 0.248, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (8)
795, d2er9E_, 0.7509, 2.79, 0.251, 328, 315, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES.
796, d1gvwA_, 0.7509, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH PD-130328
797, d5hcoA_, 0.7508, 2.72, 0.228, 323, 312, ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE
798, d1oewA_, 0.7508, 2.72, 0.293, 336, 311, ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
799, d5p3kA_, 0.7507, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 173
800, d4y48A_, 0.7507, 2.64, 0.290, 336, 310, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50
801, d1gvvA_, 0.7507, 2.81, 0.248, 330, 315, FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM
802, d1gvtA_, 0.7507, 2.73, 0.228, 323, 312, ENDOTHIAPEPSIN COMPLEX WITH CP-80794
803, d1e82E_, 0.7507, 2.79, 0.251, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD59601
804, d4lbtA_, 0.7506, 2.77, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR
805, d1e81E_, 0.7506, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395
806, d5p3pA_, 0.7505, 2.80, 0.251, 328, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 178
807, d5p1qA_, 0.7505, 2.78, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109
808, d4z22A_, 0.7505, 2.79, 0.251, 328, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
809, d4y3qA_, 0.7505, 2.78, 0.248, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109
810, d4y3jA_, 0.7505, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30
811, d5p3rA_, 0.7504, 2.79, 0.251, 328, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180
812, d5oz1A_, 0.7504, 2.79, 0.251, 328, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12
813, d1lyw.3, 0.7504, 2.79, 0.245, 330, 314, CATHEPSIN D AT PH 7.5
814, d5p6wA_, 0.7503, 2.78, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293
815, d5oyrA_, 0.7503, 2.79, 0.252, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2
816, d5hctA_, 0.7503, 2.78, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE
817, d4y3mA_, 0.7503, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103
818, d4kupA_, 0.7503, 2.84, 0.225, 329, 315, ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR
819, d2jjjA_, 0.7503, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
820, d5p5bA_, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236
821, d5p1kA_, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103
822, d5p0cA_, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 59
823, d5ozlA_, 0.7502, 2.72, 0.289, 336, 311, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32
824, d5oyxA_, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8
825, d3pbzA_, 0.7502, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
826, d5p3yA_, 0.7501, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187
827, d4yd5A_, 0.7501, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236
828, d3wz7A_, 0.7501, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (6)
829, d5p41A_, 0.7500, 2.80, 0.251, 328, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190
830, d5p3nA_, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176
831, d5p3bA_, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164
832, d5p3aA_, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163
833, d5p2nA_, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141
834, d5p0eA_, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 61
835, d5oyzA_, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10
836, d5oysA_, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3
837, d4y38A_, 0.7500, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29
838, d5p82A_, 0.7499, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335
839, d5p7cA_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309
840, d5p60A_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261
841, d5p5dA_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238
842, d5p51A_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226
843, d5p4bA_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200
844, d5p4aA_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199
845, d5p31A_, 0.7499, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154
846, d5p2bA_, 0.7499, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129
847, d5p1cA_, 0.7499, 2.79, 0.248, 329, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95
848, d5oz2A_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13
849, d5oyqA_, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1
850, d4y5bA_, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261
851, d4y44A_, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164
852, d4lhhA_, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR
853, d3pmuA_, 0.7499, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
854, d1qdmC2, 0.7499, 2.80, 0.245, 330, 314, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
855, d5p7qA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323
856, d5p6iA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279
857, d5p66A_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267
858, d5p5qA_, 0.7498, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251
859, d5p58A_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233
860, d5p4wA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221
861, d5p4lA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210
862, d5p4dA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202
863, d5p46A_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195
864, d5p43A_, 0.7498, 2.50, 0.264, 329, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192
865, d5p40A_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189
866, d5p3sA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181
867, d5p3lA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174
868, d5p37A_, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160
869, d5p34A_, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157
870, d5p33A_, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156
871, d5p2xA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150
872, d5p2jA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137
873, d5p2eA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132
874, d5p29A_, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127
875, d5p26A_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124
876, d5p00A_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47
877, d5oz4A_, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15
878, d5oyyA_, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9
879, d5oytA_, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4
880, d4y5cA_, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267
881, d4y4jA_, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97
882, d4y4bA_, 0.7498, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 323
883, d4y3hA_, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189
884, d4y3aA_, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181
885, d4y36A_, 0.7498, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4
886, d5p8hA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350
887, d5p7jA_, 0.7497, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316
888, d5p77A_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304
889, d5p76A_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303
890, d5p75A_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302
891, d5p6vA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292
892, d5p6nA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284
893, d5p6kA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281
894, d5p62A_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263
895, d5p5kA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245
896, d5p5jA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244
897, d5p5eA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239
898, d5p4zA_, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224
899, d5p4uA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219
900, d5p4tA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218
901, d5p47A_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196
902, d5p42A_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191
903, d5p3uA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183
904, d5p3tA_, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182
905, d5p3hA_, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170
906, d5p2zA_, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152
907, d5p20A_, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119
908, d5p1zA_, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118
909, d5oywA_, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7
910, d4yd3A_, 0.7497, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224
911, d1e80E_, 0.7497, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD56133
912, d5p8uA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363
913, d5p7uA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327
914, d5p7rA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324
915, d5p6jA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280
916, d5p6cA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273
917, d5p64A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265
918, d5p63A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264
919, d5p61A_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262
920, d5p55A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230
921, d5p50A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225
922, d5p4pA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214
923, d5p4nA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212
924, d5p3wA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185
925, d5p3mA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175
926, d5p3gA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169
927, d5p3eA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167
928, d5p3dA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166
929, d5p2yA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151
930, d5p2iA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136
931, d5p2fA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133
932, d5p1fA_, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98
933, d5p03A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50
934, d5p02A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49
935, d5ozvA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42
936, d5oz9A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20
937, d5oz5A_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16
938, d5oyvA_, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6
939, d4y3nA_, 0.7496, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 273
940, d4lp9A_, 0.7496, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEXED WITH PHE-REDUCED-TYR PEPTIDE.
941, d3pm4A_, 0.7496, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
942, d1gvuA_, 0.7496, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH H189
943, d5p7oA_, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321
944, d5p71A_, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298
945, d5p6xA_, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294
946, d5p6lA_, 0.7495, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282
947, d5p68A_, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269
948, d5p65A_, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266
949, d5p5yA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259
950, d5p5xA_, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258
951, d5p5wA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257
952, d5p5rA_, 0.7495, 2.81, 0.251, 328, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252
953, d5p5oA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249
954, d5p5mA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247
955, d5p5lA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246
956, d5p4vA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220
957, d5p4oA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213
958, d5p4fA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204
959, d5p49A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198
960, d5p48A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197
961, d5p45A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194
962, d5p3xA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186
963, d5p32A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155
964, d5p30A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153
965, d5p2qA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143
966, d5p2gA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134
967, d5p2dA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131
968, d5p2aA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128
969, d5p28A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126
970, d5p25A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123
971, d5p0hA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64
972, d5ozyA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45
973, d5ozqA_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37
974, d5oz8A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19
975, d5oz3A_, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14
976, d4y4eA_, 0.7495, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 131
977, d4y4dA_, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51
978, d4y43A_, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42
979, d4y3sA_, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266
980, d4y3dA_, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 321
981, d3fv3C_, 0.7495, 2.81, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
982, d5p8fA_, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348
983, d5p80A_, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333
984, d5p7sA_, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325
985, d5p72A_, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299
986, d5p6sA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289
987, d5p6qA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287
988, d5p6gA_, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277
989, d5p6fA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276
990, d5p6eA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275
991, d5p67A_, 0.7494, 2.51, 0.215, 339, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268
992, d5p5nA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248
993, d5p5cA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237
994, d5p5aA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235
995, d5p59A_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234
996, d5p53A_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228
997, d5p4cA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201
998, d5p3zA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188
999, d5p3jA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172
1000, d5p2oA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142
1001, d5p1vA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114
1002, d5p1rA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110
1003, d5p1oA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107
1004, d5p0sA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75
1005, d5p0qA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73
1006, d5p01A_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48
1007, d5ozuA_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41
1008, d5oz7A_, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18
1009, d5mb3A_, 0.7494, 2.81, 0.245, 330, 314, FRAGMENT 333 AT A CONCENTRATION OF 50MM IN COMPLEX WITH ENDOTHIAPEPSIN
1010, d5dr3A_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333
1011, d5dq2A_, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48
1012, d4ze6A_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39
1013, d4y5lA_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN ITS APO FORM
1014, d4y5eA_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268
1015, d4y4zA_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73
1016, d4y4uA_, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14
1017, d4y4tA_, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114
1018, d4y3zA_, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41
1019, d4y3yA_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42
1020, d4y39A_, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75
1021, d5p8vA_, 0.7493, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364
1022, d5p8oA_, 0.7493, 2.81, 0.248, 329, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357
1023, d5p8eA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347
1024, d5p83A_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336
1025, d5p6pA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286
1026, d5p6dA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274
1027, d5p6aA_, 0.7493, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271
1028, d5p5pA_, 0.7493, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250
1029, d5p5iA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243
1030, d5p5gA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241
1031, d5p4mA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211
1032, d5p4kA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209
1033, d5p4eA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203
1034, d5p3qA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179
1035, d5p3oA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177
1036, d5p3cA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165
1037, d5p39A_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162
1038, d5p36A_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159
1039, d5p2wA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149
1040, d5p2vA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148
1041, d5p2tA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146
1042, d5p2lA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139
1043, d5p2hA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135
1044, d5p23A_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121
1045, d5p1sA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111
1046, d5p1pA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108
1047, d5p1lA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104
1048, d5p1eA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97
1049, d5p1aA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93
1050, d5p19A_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92
1051, d5p0xA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80
1052, d5p0nA_, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70
1053, d5lwrA_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A DERIVATIVE OF FRAGMENT 177
1054, d5is4A_, 0.7493, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL BROMINATED PRIMARY AMINE FRAGMENT
1055, d5dq5A_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209
1056, d4yckA_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211
1057, d4y5kA_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274
1058, d4y5gA_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 272
1059, d4y4gA_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53
1060, d4y4aA_, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286
1061, d2h6tA_, 0.7493, 2.81, 0.245, 330, 314, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS COMPLEXED WITH PEPSTATIN A
1062, d5p8mA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355
1063, d5p8bA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344
1064, d5p7pA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322
1065, d5p73A_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300
1066, d5p70A_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297
1067, d5p6zA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296
1068, d5p6rA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288
1069, d5p6mA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283
1070, d5p6hA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278
1071, d5p6bA_, 0.7492, 2.70, 0.219, 340, 311, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272
1072, d5p5zA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260
1073, d5p5tA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254
1074, d5p5sA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253
1075, d5p5hA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242
1076, d5p54A_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229
1077, d5p4yA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223
1078, d5p44A_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193
1079, d5p2mA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140
1080, d5p1yA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117
1081, d5p1xA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116
1082, d5p1mA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105
1083, d5p1dA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96
1084, d5p1bA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94
1085, d5p17A_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90
1086, d5p0uA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77
1087, d5p0tA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76
1088, d5p0rA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74
1089, d5p0oA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71
1090, d5p0mA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69
1091, d5oznA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34
1092, d5ozkA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31
1093, d5ozjA_, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30
1094, d5mb7A_, 0.7492, 2.82, 0.245, 330, 314, COCKTAIL EXPERIMENT B: FRAGMENTS 224 AND 236 AT 50MM CONCENTRATION
1095, d5dr0A_, 0.7492, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203
1096, d4y37A_, 0.7492, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGEMENT 305
1097, d3prsA_, 0.7492, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR
1098, d1ibqA_, 0.7492, 2.81, 0.245, 330, 314, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
1099, d5p8tA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362
1100, d5p8sA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361
1101, d5p8pA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358
1102, d5p8nA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356
1103, d5p8jA_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352
1104, d5p8gA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349
1105, d5p8dA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346
1106, d5p89A_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342
1107, d5p86A_, 0.7491, 2.84, 0.244, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339
1108, d5p84A_, 0.7491, 2.79, 0.236, 325, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337
1109, d5p7yA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331
1110, d5p7vA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328
1111, d5p7kA_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317
1112, d5p7gA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313
1113, d5p78A_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305
1114, d5p6yA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295
1115, d5p6oA_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285
1116, d5p69A_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270
1117, d5p5vA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256
1118, d5p57A_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232
1119, d5p56A_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231
1120, d5p4xA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222
1121, d5p4sA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217
1122, d5p4jA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208
1123, d5p4iA_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207
1124, d5p3vA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184
1125, d5p2uA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147
1126, d5p2rA_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144
1127, d5p2kA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138
1128, d5p0zA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82
1129, d5p0wA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79
1130, d5p0gA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63
1131, d5p0fA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62
1132, d5p06A_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53
1133, d5oz6A_, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17
1134, d5oyuA_, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5
1135, d5dr1A_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278
1136, d5dq1A_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34
1137, d5dpzA_, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31
1138, d4y5nA_, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337
1139, d4y5mA_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328
1140, d4y57A_, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63
1141, d4y3tA_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207
1142, d4y3eA_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5
1143, d3pmyA_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1144, d3pi0A_, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1145, d3fv3A_, 0.7491, 2.81, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1146, d5p8rA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360
1147, d5p8qA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359
1148, d5p8lA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354
1149, d5p88A_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341
1150, d5p81A_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334
1151, d5p7mA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319
1152, d5p7lA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318
1153, d5p7iA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315
1154, d5p7eA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311
1155, d5p7dA_, 0.7490, 2.52, 0.212, 339, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310
1156, d5p7aA_, 0.7490, 2.52, 0.212, 339, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307
1157, d5p79A_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306
1158, d5p74A_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301
1159, d5p6tA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290
1160, d5p4hA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206
1161, d5p3fA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168
1162, d5p38A_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161
1163, d5p2sA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145
1164, d5p2cA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130
1165, d5p24A_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122
1166, d5p1nA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106
1167, d5p1jA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102
1168, d5p1hA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100
1169, d5p15A_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88
1170, d5p0yA_, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81
1171, d5p0pA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72
1172, d5ozdA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24
1173, d5ozbA_, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22
1174, d5lwuA_, 0.7490, 2.82, 0.245, 330, 314, STRUCTURE RESULTING FROM AN ENDOTHIAPEPSIN CRYSTAL SOAKED WITH A DIMERIC DERIVATIVE OF FRAGMENT 177
1175, d5lwtA_, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A METHOXYLATED DERIVATIVE OF FRAGMENT 177
1176, d5dr4A_, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 231
1177, d4yd7A_, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255
1178, d4y5aA_, 0.7490, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206
1179, d4y3gA_, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 285
1180, d4y35A_, 0.7490, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290
1181, d3t7qA_, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1182, d5p8iA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351
1183, d5p7zA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332
1184, d5p7xA_, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330
1185, d5p7wA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329
1186, d5p7tA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326
1187, d5p7hA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314
1188, d5p7fA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312
1189, d5p5uA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255
1190, d5p52A_, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227
1191, d5p4gA_, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205
1192, d5p35A_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158
1193, d5p1wA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115
1194, d5p1uA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113
1195, d5p1tA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112
1196, d5p1iA_, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101
1197, d5p1gA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99
1198, d5p18A_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91
1199, d5p05A_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52
1200, d5ozeA_, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25
1201, d5j25A_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158
1202, d5isjA_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL CHLORINATED PRIMARY AMINE FRAGMENT
1203, d5dr8A_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330
1204, d5dr7A_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311
1205, d4yd4A_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227
1206, d4y51A_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52
1207, d4y50A_, 0.7489, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81
1208, d4y3pA_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17
1209, d4y3lA_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205
1210, d3pgiA_, 0.7489, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1211, d3pb5A_, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1212, d5p8kA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353
1213, d5p8aA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343
1214, d5p7bA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308
1215, d5p4qA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215
1216, d5p27A_, 0.7488, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125
1217, d5p16A_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89
1218, d5p12A_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85
1219, d5p11A_, 0.7488, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84
1220, d5p0iA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65
1221, d5p08A_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55
1222, d5ozsA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39
1223, d5ozfA_, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26
1224, d5lwsA_, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 177 AND A DERIVATIVE THEREOF
1225, d4zeaA_, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91
1226, d4y4wA_, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125
1227, d4y41A_, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112
1228, d4lapA_, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP114
1229, d4l6bA_, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128
1230, d5p5fA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240
1231, d5p14A_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87
1232, d5p10A_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83
1233, d5p0vA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78
1234, d5p0aA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57
1235, d5ozzA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46
1236, d5ozxA_, 0.7487, 2.82, 0.248, 328, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44
1237, d5ozrA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38
1238, d5oziA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29
1239, d5ozhA_, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28
1240, d4yd6A_, 0.7487, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240
1241, d3lzyA_, 0.7487, 2.82, 0.245, 330, 314, CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON
1242, d3fv3H_, 0.7487, 2.82, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1243, d3fv3G_, 0.7487, 2.82, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1244, d5p8cA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345
1245, d5p87A_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340
1246, d5p7nA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320
1247, d5p3iA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171
1248, d5p22A_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120
1249, d5p13A_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86
1250, d5p0lA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68
1251, d5p0jA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66
1252, d5p0dA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60
1253, d5ozpA_, 0.7486, 2.53, 0.212, 339, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36
1254, d5ozgA_, 0.7486, 2.53, 0.212, 339, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27
1255, d5ozcA_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23
1256, d5oz0A_, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11
1257, d5iskA_, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FLUORINATED PRIMARY AMINE FRAGMENT
1258, d5dq4A_, 0.7486, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 66
1259, d4y3xA_, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171
1260, d4y3fA_, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78
1261, d3t7xA_, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1262, d3pldA_, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1263, d1zapA_, 0.7486, 2.82, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
1264, d5p85A_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338
1265, d5p6uA_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291
1266, d5p0bA_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58
1267, d5p09A_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56
1268, d5oztA_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40
1269, d5ozoA_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35
1270, d5ozmA_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33
1271, d5ozaA_, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21
1272, d4y5pA_, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338
1273, d4y56A_, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58
1274, d4y54A_, 0.7485, 2.85, 0.228, 341, 312, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 56
1275, d4y53A_, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54
1276, d4y45A_, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 291
1277, d4y3wA_, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35
1278, d3pllA_, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1279, d3fv3E_, 0.7485, 2.82, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1280, d5mb0A_, 0.7484, 2.82, 0.245, 330, 314, COCKTAIL EXPERIMENT A: FRAGMENTS 63 267 AND 291 IN COMPLEX WITH ENDOTHIAPEPSIN
1281, d3pcwA_, 0.7484, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1282, d3pbdA_, 0.7484, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1283, d2v00A_, 0.7484, 2.82, 0.245, 330, 314, X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1
1284, d5p4rA_, 0.7483, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216
1285, d5p07A_, 0.7483, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54
1286, d5ozwA_, 0.7483, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43
1287, d4y47A_, 0.7483, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 162
1288, d1od1A_, 0.7483, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN PD135040 COMPLEX
1289, d1j71A_, 0.7483, 2.82, 0.245, 330, 314, STRUCTURE OF THE EXTRACELLULAR ASPARTIC PROTEINASE FROM CANDIDA TROPICALIS YEAST.
1290, d3tneB_, 0.7482, 2.54, 0.212, 339, 307, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
1291, d3t7pA_, 0.7482, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A HYDRAZIDE DERIVATIVE
1292, d5p0kA_, 0.7481, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67
1293, d5p04A_, 0.7481, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51
1294, d4y4xA_, 0.7481, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51
1295, d3psyA_, 0.7480, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1296, d3tneA_, 0.7479, 2.82, 0.245, 330, 314, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
1297, d3pczA_, 0.7479, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BENZAMIDINE
1298, d3t6iA_, 0.7478, 2.77, 0.246, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH AN AZEPIN DERIVATIVE
1299, d3pwwA_, 0.7478, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR
1300, d2qzwA_, 0.7478, 2.62, 0.208, 334, 308, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1301, d1izeA_, 0.7478, 2.55, 0.215, 339, 307, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN
1302, d3wz6A_, 0.7477, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5)
1303, d3fv3B_, 0.7474, 2.83, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1304, d3fv3F_, 0.7472, 2.83, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1305, d4y58A_, 0.7466, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 260
1306, d4y3rA_, 0.7466, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306
1307, d5sy2B_, 0.7465, 2.55, 0.215, 339, 307, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
1308, d1htr.1, 0.7461, 2.84, 0.245, 330, 314, CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
1309, d3fv3D_, 0.7460, 2.83, 0.245, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1310, d2h6sA_, 0.7454, 2.83, 0.245, 330, 314, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS
1311, d4aa9A_, 0.7453, 2.75, 0.215, 341, 311, CAMEL CHYMOSIN AT 1.6A RESOLUTION
1312, d4yctA_, 0.7452, 2.75, 0.225, 323, 311, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216
1313, d1eagA_, 0.7452, 2.84, 0.245, 330, 314, SECRETED ASPARTIC PROTEINASE (SAP2) FROM CANDIDA ALBICANS COMPLEXED WITH A70450
1314, d3vcmB_, 0.7434, 2.55, 0.215, 339, 307, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1315, d4rldB1, 0.7426, 2.57, 0.212, 339, 307, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1316, d3lizA1, 0.7420, 2.82, 0.243, 329, 313, CRYSTAL STRUCTURE OF BLA G 2 COMPLEXED WITH FAB 4C3
1317, d1ibqB_, 0.7418, 2.81, 0.246, 329, 313, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
1318, d4rldA1, 0.7416, 2.53, 0.249, 330, 305, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1319, d2nr6A1, 0.7414, 2.94, 0.249, 372, 313, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1320, d1tzsA_, 0.7414, 2.94, 0.249, 372, 313, CRYSTAL STRUCTURE OF AN ACTIVATION INTERMEDIATE OF CATHEPSIN E
1321, d2nr6B1, 0.7413, 2.56, 0.216, 338, 306, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1322, d1yg9A1, 0.7411, 2.86, 0.218, 340, 312, THE STRUCTURE OF MUTANT (N93Q) OF BLA G 2
1323, d4ybfA_, 0.7407, 2.24, 0.275, 313, 302, ASPARTIC PROTEINASE SAPP2 SECRETED FROM CANDIDA PARAPSILOSIS AT 1.25 A RESOLUTION
1324, d4rldC1, 0.7403, 2.84, 0.246, 328, 313, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1325, d2qzwB_, 0.7401, 2.85, 0.230, 339, 309, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1326, d4rldD1, 0.7394, 2.56, 0.250, 325, 304, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1327, d3q70A_, 0.7380, 2.57, 0.160, 326, 307, SECRETED ASPARTIC PROTEASE IN COMPLEX WITH RITONAVIR
1328, d1izdA_, 0.7373, 2.58, 0.160, 327, 307, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE
1329, d3pvkA_, 0.7361, 2.58, 0.160, 327, 307, SECRETED ASPARTIC PROTEASE 2 IN COMPLEX WITH BENZAMIDINE
1330, d4ycyA_, 0.7341, 2.80, 0.240, 325, 312, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 218
1331, d3vcmA_, 0.7340, 2.58, 0.160, 326, 307, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1332, d5bwyA_, 0.7275, 2.69, 0.159, 325, 308, STRUCTURE OF PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM SPACE GROUP P43212
1333, d3vlaA_, 0.7273, 2.38, 0.265, 322, 302, CRYSTAL STRUCTURE OF EDGP
1334, d4pphE_, 0.7261, 2.69, 0.159, 325, 308, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1335, d4pphF_, 0.7256, 2.70, 0.159, 325, 308, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1336, d3vlbC_, 0.7251, 2.69, 0.221, 334, 308, CRYSTAL STRUCTURE OF XEG-EDGP
1337, d4pphB_, 0.7250, 2.53, 0.160, 326, 306, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1338, d3aupB_, 0.7250, 2.92, 0.219, 341, 311, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1339, d1t6gB_, 0.7248, 2.54, 0.160, 326, 306, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1340, d1t6gA_, 0.7245, 2.60, 0.237, 334, 304, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1341, d3vlbA_, 0.7243, 2.93, 0.225, 323, 311, CRYSTAL STRUCTURE OF XEG-EDGP
1342, d4pphC_, 0.7226, 2.48, 0.233, 330, 301, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1343, d4pphD_, 0.7223, 2.82, 0.247, 323, 308, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1344, d1t6eX_, 0.7210, 2.79, 0.250, 335, 304, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR I
1345, d4pphA_, 0.7203, 3.13, 0.229, 376, 315, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1346, d3qvcA_, 0.7177, 3.13, 0.229, 376, 315, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) ZYMOGEN FROM PLASMODIUM FALCIPARUM
1347, d3aupC_, 0.7174, 3.48, 0.149, 412, 322, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1348, d3aupA_, 0.7167, 3.48, 0.149, 412, 322, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1349, d3hd8A_, 0.7152, 3.33, 0.174, 391, 316, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1350, d1miqB_, 0.7138, 3.35, 0.177, 392, 316, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1351, d1miqA_, 0.7130, 3.46, 0.150, 403, 321, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1352, d1pfzB_, 0.7129, 3.27, 0.175, 391, 315, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1353, d1pfzA_, 0.7129, 3.17, 0.143, 372, 314, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1354, d2b42A1, 0.7124, 3.12, 0.148, 368, 311, CRYSTAL STRUCTURE OF THE TRITICUM XYLANSE INHIBITOR-I IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1355, d1pfzD_, 0.7120, 3.13, 0.148, 368, 311, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1356, d3hd8C_, 0.7108, 3.50, 0.149, 404, 322, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1357, d1pfzC_, 0.7073, 3.33, 0.175, 392, 315, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1358, d3aupD_, 0.7028, 3.33, 0.175, 392, 315, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1359, d3q6yA_, 0.7017, 3.31, 0.175, 392, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR
1360, p4trwB1, 0.6687, 3.34, 0.140, 362, 314, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
1361, p4zsrB1, 0.6619, 3.38, 0.171, 390, 315, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1362, p4zsqA1, 0.6618, 3.23, 0.226, 368, 314, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1363, p4trzA1, 0.6617, 3.38, 0.150, 372, 314, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
1364, p4zsqB1, 0.6616, 3.20, 0.151, 377, 311, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1365, p6bfxB1, 0.6613, 3.43, 0.147, 370, 312, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1366, p3lpjB1, 0.6612, 3.43, 0.147, 370, 312, STRUCTURE OF BACE BOUND TO SCH743641
1367, p3lpkA1, 0.6609, 3.22, 0.224, 375, 313, STRUCTURE OF BACE BOUND TO SCH747123
1368, p6bfxA1, 0.6608, 3.21, 0.223, 373, 310, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1369, p3lpjA1, 0.6608, 3.04, 0.221, 369, 308, STRUCTURE OF BACE BOUND TO SCH743641
1370, p3lpiA1, 0.6608, 3.03, 0.224, 370, 308, STRUCTURE OF BACE BOUND TO SCH745132
1371, p4trzC1, 0.6594, 3.29, 0.143, 364, 308, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
1372, p4tryC1, 0.6592, 3.09, 0.231, 369, 308, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
1373, p4ybiA1, 0.6589, 3.35, 0.149, 368, 309, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
1374, p4tryB1, 0.6578, 3.18, 0.221, 356, 308, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
1375, p5he5A1, 0.6532, 3.18, 0.149, 360, 303, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1376, p5hduA1, 0.6532, 2.86, 0.251, 305, 295, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1377, p5hd0A1, 0.6529, 0.71, 1.000, 267, 253, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
1378, p5v0nC1, 0.6491, 0.64, 1.000, 264, 250, BACE1 IN COMPLEX WITH INHIBITOR 5G
1379, p4trwA1, 0.6456, 0.65, 1.000, 264, 250, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
1380, p4ybiB1, 0.6433, 0.41, 1.000, 263, 249, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
1381, p4zsmB1, 0.6411, 0.66, 1.000, 264, 250, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
1382, p6bfwB1, 0.6409, 0.68, 1.000, 263, 250, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
1383, p4fseE1, 0.6408, 0.69, 1.000, 264, 250, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1384, p4fseD1, 0.6408, 0.70, 1.000, 265, 250, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1385, p4fseB1, 0.6407, 0.70, 1.000, 264, 250, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1386, p4fseA1, 0.6407, 0.71, 1.000, 265, 250, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1387, p3skfB1, 0.6390, 0.70, 1.000, 265, 250, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
1388, p3skfA1, 0.6390, 0.59, 1.000, 263, 249, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
1389, p4trzB1, 0.6381, 0.61, 1.000, 263, 249, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
1390, p3r2fE1, 0.6372, 0.67, 1.000, 263, 249, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1391, p3r2fD1, 0.6372, 0.74, 1.000, 263, 249, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1392, p3r2fB1, 0.6372, 0.69, 1.000, 262, 247, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1393, p3skgE1, 0.6371, 0.69, 1.000, 262, 247, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1394, p3skgB1, 0.6371, 0.71, 1.000, 262, 247, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1395, p3r2fA1, 0.6371, 0.79, 1.000, 252, 246, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1396, p3skgA1, 0.6370, 0.43, 1.000, 257, 243, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1397, p3skgD1, 0.6368, 0.65, 1.000, 256, 243, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1398, p3uqrA1, 0.6267, 0.59, 1.000, 255, 242, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1399, p4jooA1, 0.6197, 0.59, 1.000, 255, 242, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
1400, p6ej3A1, 0.6150, 0.61, 1.000, 255, 242, BACE1 COMPOUND 23 
1401, p3zl7A1, 0.5974, 0.61, 1.000, 255, 242, BACE2 FYNOMER COMPLEX
1402, p4ehcA_, 0.5830, 0.61, 1.000, 255, 242, CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF RV0977 OF MYCOBACTERIUM TUBERCULOSIS
1403, p4tryA2, 0.5401, 0.61, 1.000, 255, 242, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
1404, p4zspB2, 0.5382, 0.74, 1.000, 255, 242, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
1405, p4trwC2, 0.5380, 0.73, 1.000, 255, 242, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
1406, p4zsrA2, 0.5378, 0.80, 1.000, 256, 242, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1407, p6dhcA2, 0.5377, 0.67, 1.000, 254, 241, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
1408, p5hu0B2, 0.5375, 0.67, 1.000, 254, 241, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
1409, p4zspA2, 0.5375, 0.67, 1.000, 254, 241, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
1410, p3lpkB2, 0.5375, 0.68, 1.000, 254, 241, STRUCTURE OF BACE BOUND TO SCH747123
1411, p6bfdB2, 0.5374, 0.67, 1.000, 254, 241, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1412, p6bfeB2, 0.5373, 0.68, 1.000, 254, 241, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1413, p5hu0A2, 0.5373, 0.68, 1.000, 254, 241, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
1414, p4zsmA2, 0.5373, 0.70, 1.000, 254, 241, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
1415, p3lpiB2, 0.5373, 0.85, 0.996, 242, 238, STRUCTURE OF BACE BOUND TO SCH745132
1416, p6bfeA2, 0.5370, 0.98, 1.000, 252, 236, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1417, p5mbwA2, 0.5368, 0.74, 1.000, 236, 233, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH PEP#3
1418, p5htzB2, 0.5354, 1.87, 0.540, 238, 235, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
1419, p6dhcB2, 0.5352, 3.44, 0.132, 275, 257, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
1420, p5mxdA2, 0.5351, 3.44, 0.132, 275, 257, BACE-1 IN COMPLEX WITH LIGAND 32397778
1421, p6bfdA2, 0.5345, 0.34, 1.000, 203, 203, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1422, p5mxdC2, 0.5343, 0.54, 1.000, 203, 203, BACE-1 IN COMPLEX WITH LIGAND 32397778
1423, p6bfwA2, 0.5341, 0.56, 1.000, 204, 203, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
1424, p4dvfB2, 0.5337, 0.57, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1425, p6c2iA2, 0.5336, 0.63, 1.000, 203, 203, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH : N-(3-((1R5S 6R)-3-AMINO-5-METHYL-2-OXA-4-AZABICYCLO[4.1.0]HEPT-3-EN-5-YL)-4- FLUOROPHENYL)-5-METHOXYPYRAZINE-2-CARBOXAMIDE
1426, p4x7iB2, 0.5332, 0.61, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
1427, p6dhcC2, 0.5326, 0.60, 1.000, 203, 203, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
1428, p4x7iA2, 0.5326, 0.61, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
1429, p5mcqA2, 0.5314, 0.62, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR
1430, p6fgyA2, 0.5305, 0.63, 1.000, 203, 203, CRYSTAL STRUCTURE OF HUMAN BACE-1 IN COMPLEX WITH AMINO-1;4-OXAZINE COMPOUND 4 
1431, p5he7B2, 0.5302, 0.62, 1.000, 204, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
1432, p5hduB2, 0.5302, 0.62, 1.000, 203, 203, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1433, p3tplB2, 0.5302, 0.62, 1.000, 203, 203, APO STRUCTURE OF BACE1
1434, p5ygyA2, 0.5301, 0.65, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH (S)-N-(3-(2-AMINO-6- (FLUOROMETHYL)-4 -METHYL-4H-1;3-OXAZIN-4-YL)-4-FLUOROPHENYL)-5- CYANOPICOLINAMIDE 
1435, p5hu1B2, 0.5301, 0.67, 1.000, 204, 203, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
1436, p5he5B2, 0.5301, 0.55, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1437, p5he4B2, 0.5301, 0.81, 1.000, 204, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1438, p5hdvB2, 0.5301, 0.79, 1.000, 203, 203, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1439, p5hu1A2, 0.5300, 0.64, 1.000, 202, 202, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
1440, p5he7A2, 0.5300, 0.86, 1.000, 203, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
1441, p5hdxB2, 0.5300, 0.67, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1442, p5htzA2, 0.5299, 0.45, 1.000, 202, 201, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
1443, p5he4A2, 0.5299, 0.88, 0.975, 205, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1444, p5hdzB2, 0.5299, 0.75, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1445, p5hdzA2, 0.5299, 0.81, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1446, p5hdvA2, 0.5299, 0.79, 1.000, 202, 202, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1447, p5hdxA2, 0.5298, 1.09, 1.000, 205, 203, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1448, p5hd0B2, 0.5298, 1.16, 1.000, 206, 203, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
1449, p5mcoA2, 0.5285, 0.54, 1.000, 200, 200, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL- 8234 AND EXOSITE PEPTIDE
1450, p4dv9A2, 0.5277, 0.54, 1.000, 200, 200, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1451, p3uqrC2, 0.5266, 0.75, 0.990, 202, 201, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1452, p6ej2A2, 0.5264, 0.93, 0.975, 203, 202, BACE1 COMPOUND 28 
1453, p3tplC2, 0.5257, 0.55, 1.000, 200, 200, APO STRUCTURE OF BACE1
1454, p5dqcC2, 0.5252, 0.55, 1.000, 200, 200, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
1455, p4dvfA2, 0.5245, 0.55, 1.000, 200, 200, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1456, p5dqcA2, 0.5244, 0.55, 1.000, 200, 200, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
1457, p3uqrB2, 0.5236, 0.56, 1.000, 201, 200, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1458, p4fgxA2, 0.5228, 0.56, 1.000, 201, 200, CRYSTAL STRUCTURE OF BACE1 WITH NOVEL INHIBITOR
1459, p5mxdB2, 0.5210, 0.56, 1.000, 200, 200, BACE-1 IN COMPLEX WITH LIGAND 32397778
1460, p5v0nA2, 0.5193, 0.57, 1.000, 201, 200, BACE1 IN COMPLEX WITH INHIBITOR 5G
1461, p5v0nB2, 0.5175, 0.57, 1.000, 201, 200, BACE1 IN COMPLEX WITH INHIBITOR 5G
1462, p5dqcB2, 0.5170, 0.57, 1.000, 200, 200, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
1463, p3tplA2, 0.5125, 0.57, 1.000, 201, 200, APO STRUCTURE OF BACE1
